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Tuberous Sclerosis Complex (TSC) is associated with many learning, 
behavioural, neurodevelopmental and psychiatric difficulties. Over 90% of 
individuals with TSC will have some of these concerns yet no more than 20% 
receive support and treatment, even though these issues may cause the greatest 
burden of disease in TSC. The Neuropsychiatry Panel at the 2012 TSC 
Consensus Conference coined the term TAND (TSC-Associated Neuropsychiatric 
Disorders) to capture the multidimensional concerns seen in TSC, and 
recommended that each person with TSC should be screened for TAND every 
year. To facilitate the process, a TAND Checklist was designed. Many 
professionals and families feel overwhelmed by the complexity of TAND and say 
that they do not know where to start and how to access relevant information, tips 
or ‘next step’ approaches. This may in part be due to the multi-dimensionality of 
TAND, and in part due to lack of access to clear, useful and evidence-based 
resources for TAND. This project aimed to examine the complexity of TAND. The 
hypothesis was that, even though each individual will typically have their own 
unique TAND profile, there will be key natural TAND Clusters – combinations of 
behaviours across multi-dimensional levels - that will simplify further evaluations 
and treatment. The study was performed over 36 months, in two phases using a 
mixed-methods approach. Phase I was a pilot phase. TAND Checklist data were 
collected from 56 individuals with TSC in South Africa (n=20) and in Australia (n= 
36). Using R, these data were explored with various multivariate data analysis 
techniques to identify suitable analysis methods for the identification of potential 
natural TAND clusters. WARD’s cluster analysis method rendered six TAND 
clusters with good face validity, and convergence with a six-factor exploratory 
factor analysis solution. Pilot results suggested that a combination of cluster 
analysis and exploratory factor analysis methods may be able to identify clinically-
meaningful natural TAND clusters. Phase II set out to replicate and expand on 
pilot results. TAND checklist data were collected from n=453 across six 
international TSC sites, and the multivariate analysis techniques identified in 
phase I were applied. WARD’s method rendered seven natural TAND clusters 
with good clinical face validity and good statistical robustness on bootstrapping. 
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Results showed significant convergence with an exploratory factor analysis 
solution. Combining all data-driven strategies, we identified a ‘Scholastic’ cluster 
of TAND manifestations, a ‘Neuropsychological’ cluster, a ‘Mood/Anxiety’ cluster, 
an ‘ASD-like’ cluster, a ‘Dysregulated Behaviour’ cluster, a ‘Overactive/Impulsive’ 
cluster, and an ‘Eat/Sleep’ cluster. All natural clusters, apart from the Eat/Sleep 
cluster showed good to excellent internal consistency. The larger-scale study 
findings were remarkably consistent with pilot findings, supporting the robustness 
of these naturally occurring clusters. We propose that the seven natural TAND 
clusters identified can in future be used to generate educational and clinical 
resources for use in real-life settings. In addition, findings suggest that the 
aetiology and molecular treatments of TAND may also show differential clustering 
across human and animal models, pointing towards novel hypotheses regarding 
neuropsychiatric phenomena in TSC to be explored in future studies.  
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STYLE, ABBREVIATION, AND KEY TERMS 
A note on spelling and style convention: UK English spelling has been used 
throughout this thesis. I have used Harvard referencing throughout the thesis for 
the same reason, and compiled all references at the end of this thesis.  
ABBREVIATION 
ADHD Attention deficit hyperactivity disorder 
AMPK  AMP-activated protein kinase 
ASD Autism spectrum disorder 
MAPK  Mitogen-activated protein kinases 
mTOR Mammalian target of rapamycin 
TAND Tuberous sclerosis associated neuropsychiatric 
disorders 
TSC Tuberous sclerosis complex 
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KEY TERMS 
Attention deficit hyperactivity disorder (ADHD) 
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Tuberous sclerosis associated neuropsychiatric disorders (TAND) 




1.1 Background to the thesis 
This thesis has a primary focus on TSC-Associated Neuropsychiatric Disorders 
(TAND) and on a search for potential natural TAND clusters. The thesis was 
drafted to incorporate a number of peer-reviewed publications (with appropriate 
authorisation from the Doctoral Degree Board of the Faculty Health Sciences at 
the University of Cape Town). Given the multi-system nature of Tuberous 
Sclerosis Complex (TSC), the thesis will start with some general background to 
TSC, incorporating basic descriptions of the disorder and its history, the genetic 
and molecular aspects of the condition, and a topline introduction to TSC-
associated neuropsychiatric disorders (TAND). The introductory chapter will be 
followed by two further background chapters. Chapter 2 will present a recent 
update of advances in the field of TSC, will summarise the revised diagnostic 
criteria for TSC, and will comment broadly on molecular treatments for TSC. The 
core of chapter 2 will focus on TAND and development of the TAND Checklist, 
given the focus of this thesis. Chapter 3 represents a conceptual reflection on 
TAND and on the reasons why individuals with TAND around the globe receive so 
little assessment and intervention. This chapter therefore provides the scientific 
rationale for the data-based work, which is presented in chapters 4 and 5. In 
chapter 4, a pilot feasibility study is presented. The pilot study was conducted with 
the aims of testing various multivariate data analysis techniques and to ascertain 
the feasibility of identifying natural TAND clusters. The findings from this pilot 
study formed the foundation for the large-scale study comprising 453 individuals 
with TSC. In chapter 5 of the thesis this study is presented and multivariate data 
analysis techniques identified in the pilot study applied. Chapter 6 concludes the 
thesis and summarises potential next steps and limitations of the work. 
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1.2 Background to Tuberous Sclerosis Complex 
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder 
with multi-system involvement. In 1880 French physician, Bourneville, was first to 
coin the term “tuberous sclerosis of the cerebral convolutions” to describe the 
potato-like lesions seen during the autopsy of a girl who died as a result of 
seizures (Bourneville, 1880). TSC can affect virtually any organ system, with most 
commonly encountered physical manifestations being benign tumours in the 
central nervous system, skin, kidneys, heart, and lungs. TSC is also associated 
with a vast range of neuropsychiatric disorders that include behavioural problems, 
neurodevelopmental disorders, and major psychiatric disorders. 
The disorder is caused by mutations in either of two genes, the TSC1 gene on 
chromosome 9q34 (Povey et al., 1994; van Slegtenhorst et al., 1997) or the TSC2 
gene on chromosome 16p13.3. (The European Chromosome 16 Consortium 
1993; Povey et al., 1994). The encoded protein products of TSC1 (hamartin) and 
TSC2 (tuberin) regulate and integrate intracellular signalling pathways (Figure 
1.1), including the PI3K, AMPK and MAPK pathways (de Vries and Howe, 2007; 
van Slegtenhorst et al., 1997). A mutation in either of the TSC genes may disrupt 
the TSC1-TSC2 intracellular protein complex, resulting in hyperactivation of the 
mammalian target of rapamycin (mTOR) pathway. TSC is therefore an mTOR 
overactivation syndrome. The TSC-mTOR pathway is a signalling pathway that 
critically regulates cell growth and proliferation, protein synthesis, and metabolism 
(Kenerson et al., 2002; Tee et al., 2002). Developments in the molecular biology 
of TSC identified that the TSC-mTOR and related signaling pathways are also 
involved with numerous neurobiological processes including long-term 
potentiation (LTP) and synaptic plasticity, myelination, actin cytoskeletal 
formation, forebrain development, energy sensing, astrocyte morphology, and 
neuronal polarity, contributing to the neuropsychiatric phenotypes observed in 
TSC (summarised in Ehninger et al., 2008; Costa-Mattioli et al., 2009; de Vries, 
2010b).  
Serfontein and colleagues (2010) studied the evolution of the TSC1/2-TOR 
signalling pathway using complete genome sequencing and found that the 
existing pathway was built up from an ancestral one linking growth and energy 
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supply. The authors proposed that, after the divergence of the main eukaryote 
lineages, the pathway became more sophisticated in some lineages through the 
incorporation of additional input (such as TSC1-TSC2) and output elements 
(Serfontein et al., 2010).  
Figure 1.1. Intracellular signaling and the neurobiology of tuberous sclerosis complex (TSC). The 
TSC1-TSC2 protein complex acts as an intracellular complex at the crossroads of a number of 
important signaling pathways. These include the insulin-signaling PI3K-AKT pathway; the 
mitogen-activated p38MAPK and ERK1/2 pathways; and the energy-sensing AMPK pathway. 
Proteins in these pathways have fundamental neurobiological roles as represented schematically 
in the figure. 4E-BP1 = eukaryotic initiation factor 4E binding protein 1; AKT = protein kinase B; 
AMPK = adenosine monophosphate activated protein kinase; CDK1 = cyclin-dependent kinase 1; 
EIF4E = eukaryotic translation initiation factor 4E; ERK1/2 = extracellular signal regulated kinase 1 
and 2; GSK3beta = glycogen synthase kinase 3 beta; LKB1 = serine/threonine kinase 11; LTP = 
long-term potentiation; MK2 = MAPK-activated protein kinase 2; mTORC1 = mammalian target of 
rapamycin complex 1; p38MAPK = p38 mitogen-activated protein kinase; PI3K =phosphoinositide 
3 kinase; PTEN = phosphatase and tensin homolog; Rac1 = Ras-related C3 botulinum toxin 
substrate 1; Rheb = Ras homologue enriched in brain; Rho = Ras homologue gene family, 
member A; S6K1 = ribosomal p70 S6 kinase 1; TSC1 = tuberous sclerosis complex 1 protein 
(hamartin); TSC2 = tuberous sclerosis complex 2 protein (tuberin). Reproduced with permission 
from de Vries, 2010b. 
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The estimated birth incidence of TSC is 1 in 5,800 (Osborne et al., 1991; 
O’Callaghan et al., 1998). TSC appears to have an equal male/female distribution 
and is equally common in all ethnic groups and all countries. Two thirds (~70%) of 
cases occur as spontaneous mutations and the remaining ~30% are familial, 
inherited in autosomal dominant fashion (Jones et al., 1997). Routine diagnostic 
techniques indicate that a pathogenic mutation is detected in up to 85-90% of 
individuals with a clinical diagnosis of TSC and the remaining ~ 10% with ‘no 
mutation identified’ (Nellist et al., 2015; Tyburczy et al., 2015). It seems likely that 
mosaicism accounts for a significant fraction of those without an identified 
mutation (Kwiatkowski et al., 2015). There is significant phenotypic variability in 
the amount and severity of physical features of the disorder (summarised in 
Povey et al., 1994; Curatolo et al., 2008; Henske, et al., 2016). Appropriate 
management and coordination of medical specialist care is vital across the 
lifespan to limit morbidity and mortality in individuals with TSC (Krueger et al., 
2013). 
In 1967, Lagos and Gomez who were based at the Mayo Clinic, reported findings 
from a family of 71 individuals (over five generations) with TSC. These data led to 
the first set of diagnostic criteria. The so-called ‘Gomez’ criteria were revised in 
1979 (Gomez, 1979) and again in 1998 following the first TSC consensus 
conference. The aim of this conference was to develop consensus 
recommendations for diagnosis (Roach et al., 1998) and clinical management of 
individuals with TSC (Roach et al., 1999). The last ~20 years have seen a number 
of momentous advances in understanding the pathogenesis of TSC and available 
treatment options: In the 1990s, the TSC1 and TSC2 genes were discovered (The 
European Chromosome 16 Consortium 1993; and Van Slegtenhorst et al., 1997) 
and in the early 2000s, a molecular diagnostic test for TSC was launched. In 
2001, the Drosophila homologues, Tsc1 and Tsc2, were found to be involved in 
cell and organ size regulation (Potter et al., 2001; Tapon et al., 2001). It was 
further found in 2002 that tuberin (TSC2 protein) is a target of the PI3K/AKT 
signalling pathway (Potter et al., 2001; Tapon et al., 2001; Dan et al., 2002; 
Manning et al., 2002) and that the TSC1 and TSC2 proteins form an intracellular 
complex (Tee et al., 2002). These advancements led to discovering the critical 
role of the TSC genes in regulation of the mTOR pathway (Kenerson et al., 2002). 
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Thereafter, rapamycin, an mTOR inhibitor, was shown to reduce renal tumours in 
Eker rats (Kenerson et al., 2005) and mouse models (Lee et al., 2005), and to 
reduce the size of SEGAs (Franz et al., 2006) and renal angiomyolipomas in 
individuals with TSC (Bissler et al., 2008; Davies et al., 2008). There has been a 
number of large-scale clinical trials of mTOR inhibitors for peripheral organ 
systems involved in TSC, and more recently, investigating the effects of mTOR 
inhibitors on neuropsychiatric manifestations seen in TSC (summarised in 
Curatolo et al., 2015; Henske et al., 2016; ClinicalTrials.gov).  
Given these key advances in TSC, a second international TSC consensus 
conference was held in 2012 bringing together 79 individuals (with various areas 
of expertise) from 14 countries (Northrup et al., 2013; Krueger et al., 2013). 
The aim of which was to revisit and reach consensus on diagnostic criteria, 
surveillance, and treatment guidelines for individuals with TSC.  
A variety of organs are involved in TSC and manifestations can occur at various 
times during an individual’s lifespan (See Figure 1.2 for physical manifestations 
observed in TSC). One of the organ systems most commonly affected is the 
brain, with manifestations seen in 90-95% of individuals with TSC. The main 
neuropathological features of TSC are cortical dysplasias which include cortical 
tubers (CT) and white matter radial migration lines, subependymal nodules 
(SENs), and subependymal giant cell atrocytomas (SEGAs) (Franz et al., 2010; 
Kingswood et al., 2017). SENs typically occur in the area of the foramen of Monro 
in the lateral wall of the lateral ventricle and usually remain static throughout an 
individual’s lifetime. Yet, in at least one-fifth of individuals with TSC progressive 
growth of a SEN lead to SEGA. SEGAs typically occur within the first 20 years of 
life (Franz et al., 2010). They generally exceed 1cm in diameter (but can grow to 
>10cm), causing hydrocephalus, focal neurological deficits, and even death (Goh
et al., 2004). These three lesions (CT, SEN, SEGA) demonstrate shared 
histopathological features including abnormal cellular morphology, different 
regional architecture, and excessive numbers of astrocytes (Crino et al., 2010). 
For growing but otherwise asymptomatic SEGAs, either surgical resection or 
medical therapy with mTOR inhibitors can be effective treatment options (Krueger 
et al., 2010; Franz et al., 2013; Northrup et al., 2013).  
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Figure 1.2. Physical manifestations observed in TSC. From the top these show various skin and 
brain manifestations, as well as retinal hamartoma, renal angiomyolipomas, and 
lymphangiolyomyomatosis. Reproduced with permission from de Vries et al. (2017). Images kindly 
provided by Dr Chris Kingswood and Dr Raj Newaj. 
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Epilepsy is the most common neurological disorder in TSC, affecting 70-90% of 
individuals (Webb et al., 1991; Thiele, 2004; Kingswood et al., 2017). Seizure 
onset occurs within the first year of life in a significant proportion of individuals. 
Partial and partial complex seizures are common in TSC, as well as secondarily 
generalised seizures. A third of infants with TSC will develop infantile spasms and 
a proportion will develop Lennox-Gastaut syndrome (LGS), both potentially 
catastrophic epilepsy syndromes (Muzykewics et al., 2007; Kingswood et al., 
2017). Anticonvulsant medications are currently used as first-line treatment 
options for seizures. However, 60-75% of individuals with TSC who have seizures 
will develop refractory epilepsy not effectively controlled by medical therapy 
(Kwan and Brodie, 2000; Chu-Shore et al., 2010). Epilepsy surgery can be an 
effective therapeutic option, especially for children with TSC who have refractory 
epilepsy. Other treatment strategies for refractory epilepsy may include ketogenic 
diet and vagal nerve stimulation. More recently, early phase results have 
suggested that mTOR inhibitors may be an anti-epilepsy treatment in TSC. After a 
promising phase II trial (Krueger et al., 2010), a multi-centre, international trial 
was initiated to evaluate the efficacy and safety of mTOR inhibitors as adjunctive 
treatment for partial seizures in TSC (French et al., 2016; ClinicalTrials.gov: 
NCT01713946 (EXIST-3)). This study showed Everolimus (mTOR inhibitor) to 
have good efficacy as adjunctive treatment for treatment-resistant focal seizures. 
Everolimus has recently received marketing authorisation for this indication by the 
European Medicines Agency 
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicin
es/002311/human_med_001484.jsp&mid=WC0b01ac058001d124). 
The second most frequently affected organ system in TSC is the skin, with 
manifestations also seen in 90-95% of individuals with TSC (Teng et al., 2014). 
TSC skin lesions have a characteristic appearance and include hypomelanotic 
macules (oval shaped off-white spots also known as ‘ash leaf spots’), facial 
angiofibromas (small reddish spots or bumps that consist of fibrous tissue and 
blood vessels), ungual fibromas, shagreen patches (firm irregular plaque with 
coalescing papules and nodules) and “confetti” skin lesion (small hypopigmented 
macules) (Northrup et al., 2013). Even though these skin lesions are benign, they 
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may be painful and lead to bleeding. They can compromise normal functions of 
the nasal passage or nails, and distorts normal skin structures (Darling et al., 
2010).  
The kidney is affected in 80-85% of individuals with TSC across their lifespan and 
include renal cysts and angiomyolipomas (AML) (Bissler et al., 2013; Kingswood 
et al., 2017). AMLs are benign tumours composed of vascular, smooth muscle, 
and adipose tissue. Hemorrhage from renal AMLs (proportional to size) can 
cause serious issues and lead to need for dialysis, renal transplantation, and 
sometimes mortality in adults with TSC (Bissler and Kingswood, 2004; Patel et 
al., 2005; Bissler et al., 2013). 
Ophthalmological features include retinal hamartomas and are seen in ~50% of 
individuals with TSC (Thiele and Jozwiak, 2010; Kingswood et al., 2017). These 
lesions have similar histological features to the brain tubers seen in TSC, are 
generally benign and typically do not affect vision (Northrup et al., 2013). 
Cardiac rhabdomyomas are the earliest detectable hamartoma, often seen on 
foetal ultrasound or foetal MRI, and are the only lesions in TSC likely to regress 
with age (Jozwiak and Respondek-Liberska, 2010). These tumours are believed 
to occur in 50% of individuals with TSC (summarised in Jozwiak and Respondek-
Liberska, 2010; Kingswood et al., 2017) and can be associated with cardiac 
arrhythmias including atrial and ventricular arrhythmia and Wolff-Parkinson-White 
syndrome (O’Callaghan et al., 1998). 
Lymphangioleiomyomatosis (LAM) is the primary pulmonary manifestation of TSC 
and occurs predominantly in females (Costello et al, 2000; Franz et al., 2001; 
Kingswood et al., 2017). Cystic pulmonary parenchymal changes consistent with 
LAM are observed in 30-40% of female patients with TSC, although these women 
are frequently asymptomatic (summarised in McCormack and Henske, 2010; 
Northrup et al., 2013; Kingswood et al., 2017). LAM is characterised by a 
proliferation of smooth muscle cells in nodules throughout the lung and 
associated with interstitial expansion of the lung (Northrup et al., 2013).  
TSC has a clear age-related expression pattern (see Figure 1.3), with some 
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features more prevalent during infancy and childhood and others more likely to 
manifest during adolescence or in adulthood (summarised in Crino et al., 2006; 
Curatolo et al., 2008; Henske et al., 2016). 
Figure 1.3. Age dependant expression of clinical manifestation in TSC. Reproduced with 
permission from Curatolo, P., Bombardieri, R., and Jozwiak, S. (2008).  
At present no known cure exists for Tuberous Sclerosis Complex. Nevertheless, 
an understanding of the functional relationship between the TSC1-2 complex and 
mTOR has led to significant clinical advances in the use of mTOR inhibitors. 
Everolimus (Votubia®, Afinitor ®) has been licenced by the European Medicines 
Agency (EMA) and Federal Drug Administration (FDA) for the treatment of SEGA 
not amenable to surgery, for angiomyolipomas >3cm, and, in Europe, for the 
adjunctive treatment of focal seizures. There are ongoing studies of mTOR 
inhibitors for the treatment of various physical manifestations of TSC including 
SEGA, AML, skin, LAM and epilepsy (NCT00789828; NCT00790400; Krueger et 
al., 2013). There are also several trials underway studying the efficacy and safety 
of mTOR inhibitors across neurological and neuropsychiatric manifestations. See 
Table 1.1 for clinical trials underway registered on ClinicalTrials.gov.  
Table 1.1 Summary of key interventional neuropsychiatric and clinical trials in Tuberous Sclerosis, reproduced with permission from Curatolo et al., 2015 








To assess the safety and efficacy of everolimus 
in children and young adults with tuberous 
sclerosis. Outcome measures included 
standardised neuropsychological instruments 
To identify signs of change in epilepsy, 
sleep, autism spectrum characteristics, 
academic skills, and behavioural difficulties 





To assess the efficacy of everolimus in the 
treatment of neuropsychological deficits. 
Outcome variables include episodic memory, 
planning, spatial working memory, and dual 
tasking 
To identify additional neuropsychiatric 
markers of change. Measures include 
psychiatric questionnaires, quality of life, 
adaptive behaviours, and autism rating 
scales 






To assess the feasibility and safety of mTOR 
inhibitors in children with tuberous sclerosis and 
self-injurious behaviour. Outcome measures 
include compliance, carer burden, and parental 
Stress 
To measure behavioural change 
(including self-injury, repetitive behaviours, 
and autism characteristics) and EEG and 
MRI changes 





To assess the efficacy of everolimus in the 
treatment of autism and neuropsychological 
deficits in children with intellectual disability. 
Primary outcome is intelligence quotient as 
measured by the Wechsler Preschool and 
Primary Scale of Intelligence 
To assess efficacy on other 
neuropsychiatric characteristics. 
Outcome variables of interest include 
autism, working memory and attention, 





1.3 The Neuropsychiatric Phenotype of TSC 
 
Individuals with TSC could present with a variable range of neuropsychiatric 
challenges across multiple levels (de Vries, 2010a; de Vries et al., 2015a). These 
range from behavioural difficulties, psychiatric disorders, intellectual disability, 
academic/scholastic disorders, to neuropsychological deficits and psycho-social 
difficulties. A more detailed review of the neuropsychiatric phenotype is presented 
in Chapter 2.  
 
Over 90% of individuals with TSC will have some of these concerns yet no more 
than 20% receive support and treatment (de Vries et al. 2015a), even though 
these issues may cause the greatest burden of disease in TSC. Even more recent 
data support this view (Kingswood et al., 2017). The Neuropsychiatry Panel at the 
2012 TSC Consensus Conference coined the term “TAND” (TSC-Associated 
Neuropsychiatric Disorders) to capture the multidimensional concerns seen in 
TSC, and advocated that each person with TSC should be assessed for TAND 
every year (Krueger et al., 2013; de Vries et al., 2015a). In order to facilitate the 
screening process, a TAND Checklist was developed for use as a tool to guide 
healthcare teams in a systematic investigation across the levels of 
neuropsychiatric investigation seen in TSC (de Vries et al., 2015a; Leclezio et al., 
2015). These will be discussed in more detail in chapter 2. 
 
There has fortunately been a growing recognition of the importance of TAND, and 
interest in measuring TAND for clinical trial and clinical service delivery purposes. 
However, the multi-level nature has made it very difficult to measure and quantify 
TAND in a quick, affordable, yet robust and scientifically meaningful way. There 
are a number of key challenges contributing to the complexity of assessing and 
treating TAND. These will be discussed in more detail in chapter 3. In short, we 
propose that there has been a combination of poor awareness, a perceived 
complexity of TAND, and a consequential inability of clinical teams to identify and 
treat specific aspects of TAND. This has resulted in the under-identification and 
under-treatment of TAND around the globe. 
 
The overarching thesis of the work presented here propose that TAND data may 
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show natural clustering and that by using data-driven strategies we may be able 
to identify a manageable number of natural TAND clusters. This in turn, we 
propose, would be able to improve assessment, intervention and education about 
TAND. Even though there have been no apparent clinical indications of natural 
clustering of TAND to date (Leclezio and de Vries, 2016), we based our 
hypothesis on observations of natural clustering in other model systems and 
genetic disorders. For instance, in a study of the behavioural phenotype of 
humans with Cornelia de Lange Syndrome (CdLS), categorical principal 
component analysis (PCA) was used as a data reduction tool and to describe 
relationships between a large number of behavioural variables (Wulffaert et al., 
2009). This methodology allowed for new insights into the relationships between 
physical and behavioural characteristics and into genotype-phenotype 
correlations.  
 
In this study, we propose that multivariate data analysis techniques could be 
applied as a novel strategy in TSC to reduce the multi-dimensionality of data, and 
to identify natural TAND clusters. We posit that it would be of great significance to 
identify a small number of clusters that could help to reduce and make 
manageable the complexity of TAND. We also suggest that this strategy may, in 
future, be helpful both for the detection of aetiological subgroups or subtypes in 
TSC, and for a more personalised management and treatment approach in 
clinical settings. 
 
1.4 Aims of the Thesis 
 
The general aim of this study was to identify natural TAND clusters. The specific 
aims were: 
(a) To review the current knowledge about TAND and reflect on the factors that 
may contribute to the ‘assessment and treatment gap’ for TAND. 
(b) To pilot a range of statistical methodologies using multivariate data analysis 
techniques towards identification of natural TAND clusters. 
(c) To apply the pilot study methodology to a large sample to verify and expand 
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Chapter 2  
 
 
ADVANCES IN THE TREATMENT OF TUBEROUS SCLEROSIS 
COMPLEX 
 
Leclezio, L. and de Vries, P.J. (2015) Current Opinion in Psychiatry, 28, 113-120 
 
 
2.1 Introduction  
 
Tuberous sclerosis complex (TSC) is a multi-system disorder that can affect 
virtually any organ system, with some manifestations more prevalent than others 
across the lifespan (Crino et al., 2006; Curatolo et al., 2008). The most common 
manifestations include benign tumours in the heart, kidneys, lungs, skin and 
brain. Often overlooked, TSC also includes a vast range of neuropsychiatric 
disorders, typically neurodevelopmental, behavioural and psychiatric difficulties. 
Significant phenotypic variability in the number and severity of physical features 
and neuropsychiatric manifestations are seen in TSC (Povey et al., 1994; de Vries 
et al., 2010; de Vries et al., 2015a). 
 
The disorder is caused by mutations in either of two genes, the TSC1 gene on 
chromosome 9q34 (Povey et al., 1994; van Slegtenhorst et al., 1997) or the TSC2 
gene on chromosome 16p13.3 (The European Chromosome 16 Consortium, 
1993; Povey et al., 1994). The birth incidence of TSC is estimated to be 1 in 
6,000 (Osborne et al., 1991; O’Callaghan et al., 1998; Thiele and Jozwiak, 2010) 
and seems to have an equal male/female distribution. Up to 75% of cases occur 
as spontaneous mutations and the remaining ~25% are inherited in an autosomal 
dominant manner (Crino et al., 2006). Currently there is no known cure for 
Tuberous Sclerosis Complex. However, an understanding of the functional 
relationship between the TSC1-TSC2 complex and mTOR has led to important 
clinical advances in the use of mTOR inhibitors as molecularly targeted 
treatments of the mTOR overactivation caused by mutations in either the TSC1 or 
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TSC2 gene (Povey et al., 1994; van Slegtenhorst et al., 1997). Given the multi-
system nature of the disorder, appropriate management and coordination of 
specialist care is crucial across the lifespan to limit morbidity and mortality in this 
disease and to optimize quality of life (Krueger et al., 2013). 
 
Here we review three main themes that emerged from the TSC literature over the 
last 18 months. Firstly, the revised diagnostic criteria and 
surveillance/management guidelines (Krueger et al., 2013; Northrup et al., 2013). 
The revised criteria and monitoring guidelines emerged from the 2012 
International TSC Consensus Conference. At the consensus conference, the 
Neuropsychiatry Panel coined a new term – Tuberous Sclerosis Associated 
Neuropsychiatric Disorders (TAND). We next review the two recent papers 
around TAND and a TAND Checklist developed by the Neuropsychiatry panel as 
a potential screening tool for TAND (de Vries et al., 2015a; Leclezio et al., 2015). 
Finally, in view of the rapid progress around molecularly targeted treatments of 
the physical manifestations of TSC, we discuss the advances and debates around 
molecular treatments for the neuropsychiatric features of the disorder (Bissler et 
al., 2013; Franz et al., 2013). 
 
2.2 International TSC Consensus guidelines and recommendations 
 
Lagos and Gomez, based at the Mayo Clinic reported in 1967 the findings from a 
five generation family of 71 individuals affected by TSC. These data led to the first 
set of diagnostic criteria proposed by Gomez. The so-called ‘Gomez’ criteria were 
revised in 1979 (Gomez, 1979). In 1998, the National Institutes of Health (NIH) 
sponsored a conference with the aim to develop consensus recommendations for 
diagnosis (Roach et al., 1998) and clinical management of individuals with TSC 
(Roach et al., 1998; Gomez et al., 1999).  
 
The last 15 years have however seen a number of significant advances in 
understanding the pathogenesis and potential treatments of TSC. The TSC1 and 
TSC2 genes had been identified just before the 1998 consensus conference, but 
the roles of the putative ‘tumour suppressor genes’ were unknown. In 2002/2003 
the discovery was made that the TSC1 and TSC2 proteins interact with one 
another, and that they act as a key signalling protein in the PI3K-mTOR 
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intracellular signalling pathway. This immediately led to insight into the 
pathophysiological mechanism of TSC and showed that loss of either gene leads 
to overactivation of mTOR (Kennerson et al., 2002; Tee et al., 2002). At the time, 
rapamycin, the prototypical mTOR inhibitor, was already licensed by the FDA for 
use in organ transplant. Very rapidly, the TSC community therefore moved to 
clinical trials of mTOR inhibitors. The first phase III double-blind, placebo-
controlled trials of everolimus, an mTOR inhibitor, were published and showed 
evidence of shrinkage of subependymal giant cell astrocytomas (SEGA) and of 
renal angiomyolipomas (Bissler et al., 2013; Franz et al., 2013). Everolimus was 
licensed for use in TSC in 2012 by the FDA and European Medicines Agency 
(EMA) (Talan, 2010).  
 
Given the key advances in TSC, there was growing interest in convening a 
consensus conference to reassess the diagnostic criteria, to consider the role of 
mutational analysis in diagnosis, and in particular, to improve the monitoring and 
treatment guidelines for the disorder given evidence from clinical trials. The 
second International TSC consensus conference was held in June 2012 in 
Washington DC, and brought together 79 individuals from 14 countries to review 
and reach consensus on diagnostic, surveillance, and management 
recommendations for individuals with TSC (Northrup et al., 2013; Krueger et al., 
2013). Table 2.1 shows the updated diagnostic criteria for Tuberous Sclerosis 
Complex. 
 
Table 2.1 Revised diagnostic criteria for tuberous sclerosis complex 2012, (Northrup et al., 2013)   
 
A. Genetic diagnostic criteria 
 
The identification of either a TSC1 or TSC2 pathogenic mutation in DNA from 
normal tissue is sufficient to make a definite diagnosis of Tuberous Sclerosis 
Complex (TSC). A pathogenic mutation is defined as a mutation that clearly 
inactivates the function of the TSC1 or TSC2 proteins (e.g., out-of-frame indel or 
nonsense mutation), prevents protein synthesis (e.g., large genomic deletion), or 
is a missense mutation whose effect on protein function has been established by 
functional assessment. Other TSC1 or TSC2 variants whose effect on function is 
less certain do not meet these criteria, and are not sufficient to make a definite 
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diagnosis of TSC. Note that 10% to 25% of TSC patients have no mutation 
identified by conventional genetic testing, and a normal result does not exclude 
TSC, or have any effect on the use of clinical diagnostic criteria to diagnose TSC.  
B. Clinical diagnostic criteria  
Major features  
1. Hypomelanotic macules (≥3, at least 5-mm diameter)  
2. Angiofibromas (≥3) or fibrous cephalic plaque 
3. Ungual fibromas (≥2) 
4. Shagreen patch  
5. Multiple retinal hamartomas 
6. Cortical dysplasias* 
7. Subependymal nodules 
8. Subependymal giant cell astrocytoma 
9. Cardiac rhabdomyomatosis 
10. Lymphangioleiomyomatosis (LAM)** 




1. “Confetti” skin lesions 
2. Dental enamel pits (>3) 
3. Intraoral fibromas (≥2) 
4. Retinal achromic patch 
5. Multiple renal cysts 
6. Nonrenal hamartomas 
 
Definite diagnosis: Two major features or one major feature with ≥2 minor 
features 
Possible diagnosis: Either one major feature or ≥2 minor features 
 
* Includes tubers and cerebral white matter radial migration lines 
** A combination of the two major clinical features (LAM and angiomyolipomas) 




Some of the important changes in comparison to the 1998 diagnostic criteria 
included the addition of a genetic criterion for TSC. Tuberous sclerosis can 
therefore now be diagnosed in the presence of a definite pathogenic mutation 
(see Table 2.1). The clinical criteria have remained very similar, apart from subtle 
improvements in, for instance, the number and size of physical characteristics 
required to be regarded as a ‘major’ criterion. Another change was removal of the 
category of ‘probable TSC’. Under the new diagnostic criteria, a diagnosis is 
either ‘definite’ when 2 or more major criteria, or 1 major and 2 or more minor 
criteria are present, OR is ‘possible’ when only 1 major or 2+ minor criteria are 
present. 
 
The surveillance and management guidelines used an evidence-based approach 
to collect levels of evidence for monitoring and treatment, and has resulted in an 
extremely useful set of guidelines for use in clinical practice. The guidelines 
presented clear rationales for monitoring and presented well-balanced and well-
considered recommendations for investigations and interventions (Krueger et al., 
2013). 
 
2.3 TSC-Associated Neuropsychiatric Disorders (TAND) 
 
A wide range of behavioural, psychiatric, intellectual, academic, 
neuropsychological and psycho-social concerns are observed in individuals with 
TSC. Some of the high frequency difficulties across these levels of investigation 
are shown in Table 2.2. The table also indicates the typical tools used to assess 













Table2.2. TSC-Associated Neuropsychiatric Disorders 
Level of 
Investigation 
Assessment tools Examples  Rates References 
1. Behavioural Direct observation, 
parent and carer 
surveys, rating 
scale measures 
 Anxiety   
 Depressed mood  
 Overactivity, restlessness and impulsivity  
 Aggression    
 Temper tantrums    
 Self-injury    
 Social-communication difficulties (including poor eye contact, repetitive and ritualistic 
behaviours, speech & language delay) 
 Sleep    
 
The significant variability in rates of behavioural difficulties can at least in part be explained by the 






















2. Psychiatric DSM-IV/5 (APA, 
1994) and/or ICD-
10 (WHO, 1993) 
 Autism Spectrum Disorders    
 
Estimates of prevalence rates of Autism Spectrum Disorders (ASD) in individuals with TSC have 
been reported at much higher rates than expected, ranging from 17-61%. The variability in these 
rates can be explained by the definition of ASD being used (classic autism versus autism 
spectrum disorders), the methodology employed (clinic based studies versus population based) 
and the level of intellectual ability of participants. The most comprehensive and detailed 
population-based study using the ADOS and ADI-R showed that 26% of children with TSC across 
all levels of intellectual ability met criteria for classic infantile autism and that about 50% met 
criteria for an ASD. 
 





























General population rates of ADHD vary significantly and much of this variability could be explained 
by the different methodologies employed by researchers. A systematic review and meta-analyses 
of 102 studies comprising 171,756 subjects from around the globe showed that the ADHD 
worldwide-pooled prevalence was 5.29%. In contrast to the general population rate, the 
prevalence of ADHD in TSC is as high as 50% in all individuals with TSC, and ~30% in those with 
normal IQ. 
 
 Mood Disorders 

























 Normal intellectual ability  
 Mild-moderate intellectual disability  
 Severe-Profound intellectual disability  
 
The majority of individuals with TSC (~70%) will have intellectual ability that falls on a normal 
distribution similar to that of the general population except that the mean IQ score is shifted 



















To date there have been no direct studies of the rates and types of learning disorders individuals 
with TSC suffer from. Rating scale measures suggest that at least 30% of children with TSC who 








 Attentional deficits (sustained attention, dual tasking) 
 Memory deficits 








 Executive deficits (planning, set shifting, sequencing, verbal fluency) 
 Specific Language deficits  
 
The pattern and rates of neuropsychological skills in TSC varies significantly across age, and may 
vary based on measurement tools used. The rates reported above are all based on performance 












parent & carer 
surveys, self report 
 Self-esteem 
 Family stress 
 Sibling difficulties 
 Peer relationship difficulties 
 
There have been no studies to date to quantify the rates of psycho-social difficulties in TSC. 
  
7. Biological Impact of the 
physical 
manifestations of 




 Epilepsy    
 Antiepilepsy medication 
 Subependymal giant cell astrocytomas 
 Renal failure 
 
Many biological factors may play a potential role in the bio-psycho-social presentation of an 
individual with TSC. The items listed above all have a strong correlation with TAND, and should be 
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Neuropsychiatric disorders seen in TSC are some of the top concerns for families 
and individuals with TSC, and have an enormous impact on quality of life. Taking 
together all the levels of investigation listed, around 90% of individuals with TSC 
will have one or more of these concerns during their lifetime (de Vries, 2010a; de 
Vries et al., 2015a). A survey of Tuberous Sclerosis Association members in the 
United Kingdom in 2010 indicated that only 18% of individuals with TSC had ever 
received an assessment or treatment for neuropsychiatric disorders (de Vries et 
al., 2015a). These results indicated a significant treatment gap of around 70%. 
 
At the TSC consensus conference in 2012, the neuropsychiatry panel expressed 
concern about the enormous treatment gap, and about the lack of clarity and 
consistency in the use of terminology across the levels of neuropsychiatric 
investigation. For instance, it was clear from the literature that terms such as 
‘behavioural difficulties’, ‘neurocognitive issues’, neurobehavioural problems’, 
‘psychiatric disorders’ and ‘developmental disability’ were all used 
interchangeably, even in relation to pre-clinical animal studies (de Vries et al., 
2015a).   
 
In an attempt to increase awareness of the burden of these difficulties, to increase 
the likelihood of screening for these problems, and to standardise terminology, 
the Neuropsychiatry Panel decided to coin the term TAND, TSC-Associated 
Neuropsychiatric Disorders, and recommended that all individuals with TSC 
should be screened for TAND at least annually (de Vries et al., 2015a; Krueger et 
al., 2013). To facilitate this process of screening, the Neuropsychiatry Panel 
agreed to develop a TAND Checklist for use as a potential screening tool. The 
panel were clear that they did not want to generate a ‘diagnostic’ tool, but rather a 
screening ‘Checklist’ to guide healthcare teams in a systematic enquiry across the 
levels of neuropsychiatric investigation required in TSC. Checklists are typically 
aimed at reducing errors of omission and are generally easy to administer and 
understand (Scriven, 2005). From a practicability point of view, the panel aimed to 
develop a checklist that would be straightforward to administer, comprehensive 





2.4 The TAND Checklist 
 
The TAND Checklist consist of a pen-and-paper, double-sided, 2 page form and 
contains a set of questions that can be used to guide a 10 minute conversation 
between an appropriate healthcare provider (e.g. clinic nurse, counsellor, doctor) 
and a parent, caregiver or individual with TSC. 
The TAND Checklist includes 7 basic developmental milestones items, 3 items on 
current level of functioning, 38 items across behaviour (19 items), psychiatric 
diagnosis (6 items), perceived intellectual disability (3 items), scholastic difficulties 
(4 items), neuropsychological skills (6 items), and psycho-social functioning (3 
items). The TAND Checklist also includes a parent/caregiver/self-rating of the 
impact of TAND (on a scale of 1-10), and a similar item where the healthcare 
provider who completes the TAND Checklist with the person provides an overall 
TAND impact score (on a scale of 1-10). Two items allow for prioritisation of next 
steps and addition of extra concerns. An individual’s TAND profile may change 
over time, thus supporting the need for re-evaluation on a regular basis. The 
TAND Checklist is presented in the appendix of the thesis. 
 
As a screening tool, it is important that the TAND Checklist is regarded to have 
face validity (seen by professionals and families as capturing the essential and 
important aspects of concern), content validity (judged by experts to cover the 
range and depth of neuropsychiatric concerns of relevance to TSC), and 
transferability (the ability of the tool to be used across different settings by 
different people). Pilot validation of the TAND Checklist was performed by 
Leclezio and colleagues in 2014. In the study mixed-methods were used across 
two stages. In stage 1 feedback was gathered on the Checklist from 20 
international TSC experts and 42 parents/carers. The aim was to examine face 
and content validity. Stage 2 involved the administration of the refined TAND 
Checklist to 20 South African parents of individuals with TSC concurrently with 
four other validated assessment tools. The aim of this stage was to examine 
concurrent validity and to obtain qualitative feedback on face-to-face 
administration of the TAND Checklist. Expert clinicians as well as families rated 
the TAND Checklist to have good face and content validity as reflected in 
quantitative analysis which showed high overall mean and median scores of 4 
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and 5 (five being the maximum rating). Stage 2 results showed moderate to very 
good correlations across key domain and subdomain scores examined. The 
TAND Checklist behavioural domain scores correlated very strongly with the 
Strength and Difficulties Questionnaire scores, with a Spearman Rho of 0.83 (p≤ 
0.001). On the neuropsychological subdomain of executive function, the TAND 
Checklist correlated strongly with that of the BRIEF behaviour rating index 
(Spearman Rho of 0.75 and p=0.001). These results suggest good concurrent 
validity with the other four assessment tools used. Findings suggested that this 
simple tool may be a helpful aide memoire in the identification and subsequent 
treatment of TAND. Results of other aspects of validity and qualitative feedback 
were used to shape the Checklist to be both clinically meaningful and a useful 
research tool for future studies (Leclezio et al., 2015). 
 
2.5 The hope of molecularly targeted treatments for the neuropsychiatric 
manifestations of TSC 
 
Molecular treatments for the physical manifestations of TSC are now a reality, 
and the international consensus conference have recommended mTOR inhibitors 
as first-line treatment for renal angiomyolipoma larger than 3cm, and as a medical 
treatment option for subepepdymal giant cell astrocytomas not amenable to 
surgery (for instance, where anaesthetic is contra-indicated, where likelihood of 
resection is low, for bilateral SEGA etc) (Bissler et al., 2013; Franz et al., 2013; 
Krueger et al., 2013). Both phase III trials reported in 2013 also observed 
systemic benefits, particularly in skin manifestations (Bissler et al., 2013; Franz et 
al., 2013). 
 
Given the positive progress in mTOR inhibitor trials, there has been growing 
interest in the possibility of mTOR inhibitors to treat some of the neuropsychiatric 
manifestations of TSC. In 2007 de Vries and Howe suggested a direct molecular 
pathway from genes to cognition and neurodevelopment in TSC, and suggested 
that rapamycin and other mTOR inhibitors might therefore improve or reverse 
some of these deficits too (de Vries and Howe, 2007). There has been some 
support from the animal literature for this hypothesis, including studies that have 
shown reversal of learning and social deficits in TSC mouse models (Ehninger et 
al., 2012; Sato et al., 2012; Tsai et al., 2012).  
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There are a number of phase II clinical trials underway examining the role of 
mTOR inhibitors for this purpose in humans (see clinicaltrials.gov). To date, there 
has only been one early-phase study of neuropsychological skills in humans 
Davies et al., 2011). In a phase II study using sirolimus, an mTOR inhibitor, to 
treat angiomyolipomas in individuals with TSC and/or sporadic 
lympangioleiomyomatosis (LAM), neuropsychological tests of memory and 
executive skills were administered to the eight adult participants with TSC at 
baseline, 4 months and 12 months. Immediate recall memory (‘free recall’) 
improved in seven of the eight participants and deteriorated in the remaining 
patient. Immediate recognition memory remained unchanged in three of the TSC 
participants and deteriorated in the remaining five. Executive skills improved in 
five of the eight participants, remained unchanged in 2, and dropped in one 
participant. Examination of the graphic representation did not show any 
association between improvement or deterioration within participants. In terms of 
recall memory, it appeared that baseline performance might have predicted 
direction of change, but this did not appear to be the case for the executive skills 
(Davies et al., 2011). 
 
There is evidence from the animal literature that mTOR inhibition may not be 
inevitably positive. Rapamycin decreased neurodevelopmental outcomes in wild-
type mice (Tsai et al., 2013), and prenatal administration of rapamycin to a TSC 
mouse model was not associated with positive outcome on behaviour tasks, in 
contrast to post-natal administration of rapamycin (Way et al., 2012).  
 
In the field of TSC there is great interest in early and even pre-emptive treatment 
of individuals with TSC (Jozwiak et al., 2011). Results from the animal models, 
and the very limited human data, however, suggest that great caution, and many 
further explorations are required to determine the optimal timing for mTOR 
inhibition in the growing brain, and to establish how to identify those who are likely 
to improve as opposed to deteriorate in neuropsychological (or other 
neuropsychiatric level) performance. We suggest that in the central nervous 
system, particularly the growing brain, a therapeutic model of ‘optimal mTOR 
signalling’ should be sought, both in terms of optimal timing of treatment, in 
relation to dynamic neurobiological processes, and in terms of optimal level of 
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inhibition, in relation to baseline mTOR activation and/or the dynamic demands of 
mTOR activation during neuropsychological task performance.  
 
2.6 Key Points 
 
 Revised diagnostic criteria for TSC, including a genetic criterion, and 
evidence-based guidelines for the surveillance and management of TSC 
were published in 2013. 
 Even though 90% of individuals with TSC will have neuropsychiatric 
difficulties during their lifetime, only about 20% ever receive evaluation and 
treatment. 
 The term TAND (TSC-Associated Neuropsychiatric Disorders) was coined 
as an umbrella term for the multiple and complex bio-psycho-social 
challenges seen in TSC. 
 All individuals with TSC should be screened for TAND at least annually. A 
TAND Checklist was developed as a potential screening tool. 
 In spite of the future promise of mTOR inhibitors to treat neuropsychiatric 
aspects of TSC, we propose a model of ‘optimal mTOR signalling’ in the 





Here we reviewed three themes of recent development in TSC of relevance to 
psychiatry, neuropsychiatry and the mental health of individuals with TSC. The 
majority of individuals with TSC will have some neuropsychiatric problems in their 
lifetime, with lifetime prevalence rates in the region of 90%. The vast range of 
challenges seen in TSC that emerge and change over developmental time and 
across dimensions can make it very difficult to know how to prioritise clinical 
concerns in order to develop next step strategies. No obvious ‘natural clusters’ of 
TAND profiles have been identified to date, and this may be a fruitful future 
strategy to explore. It is possible that distinct clusters of TAND may lead to better 
aetiological subtyping, identify profiles of clinical needs, and may guide treatment 
decisions for individuals with the disorder.  
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2.8 Chapter summary 
 
Tuberous Sclerosis Complex (TSC) is a multi-system genetic disorder with 
physical and neuropsychiatric manifestations and significant research progress 
has been made in recent years. Here we focus on key advances over the last 18 
months. Three main themes were identified in the literature. Firstly, the diagnostic 
criteria and surveillance guidelines for TSC were revised, incorporating a genetic 
criterion alongside clinical criteria, and making a positive step towards evidence-
based treatment of TSC. Secondly, a new term – TSC Associated 
Neuropsychiatric Disorders (TAND) – was introduced as an umbrella term for all 
possible neuropsychiatric difficulties seen in TSC, and a TAND Checklist was 
developed as a screening tool. Thirdly, the risks and benefits of molecularly 
targeted treatments of the neuropsychiatric manifestations of TSC are being 
debated. The updated diagnostic criteria and management guidelines, the new 
concept of TAND, and the TAND Checklist should lead to significant 
improvements in the quality of care for individuals with TSC. The promise of 
mTOR inhibitors and other molecular treatments are still to be confirmed. We 
suggest that great care should be taken to identify ‘optimal mTOR signalling’ in 











TOWARDS AN IMPROVED UNDERSTANDING OF TSC-
ASSOCIATED NEUROPSYCHIATRIC DISORDERS (TAND) 
 





Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder 
with multi-system involvement (Crino et al., 2006; Curatolo et al., 2008; Curatolo 
et al., 2015). The disorder can affect virtually any organ system in the body, with 
the most common physical manifestations being benign tumours in the central 
nervous system, skin, kidneys, heart, and lungs (Crino et al., 2006; Curatolo et 
al., 2008; Northrup et al., 2013). There is significant phenotypic variability in the 
number and severity of physical features of the disorder (Povey et al., 1994; Crino 
et al., 2006; Curatolo et al., 2008; Krueger et al., 2013; Curatolo et al., 2015). 
TSC has a clear age-related expression pattern, with some features more 
prevalent during infancy and childhood and others more likely to manifest during 
adolescence or in adulthood (Crino et al., 2006; Curatolo et al., 2008; Curatolo et 
al., 2015). Appropriate management and coordination of medical specialist care is 
crucial across the lifespan to reduce morbidity and mortality in individuals with 
TSC (Krueger et al., 2013, Curatolo et al., 2015). 
 
TSC is also associated with a vast range of neuropsychiatric disorders that 
include behavioural problems, neurodevelopmental disorders, and major 
psychiatric disorders. The term TSC-Associated Neuropsychiatric Disorders 
(TAND) was recently introduced as an umbrella term for all these potential 
difficulties (de Vries et al., 2015a; Curatolo et al., 2015). The majority of 
individuals with TSC will have some neuropsychiatric problems in their lifetime, 
with lifetime prevalence rates in the region of 90% (de Vries et al., 2015a). TAND 
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also has an age-related expression pattern, thus supporting the need for regular 
screening and comprehensive evaluation of these difficulties as set out in the 
monitoring guidelines for TSC (de Vries, 2010a; Krueger et al., 2013; Curatolo et 
al., 2015; Kingswood and de Vries, 2015). 
 
3.2 The Neuropsychiatric Phenotype of TSC 
 
There is no doubt that the neuropsychiatric disorders seen in TSC are some of 
the top concerns for families and have an enormous impact on quality of life for all 
who live with the condition (de Vries et al., 2015a; Curatolo et al., 2015). Infants, 
children, adolescents and adults with TSC may present with a varied and variable 
range of neuropsychiatric challenges across multiple levels or dimensions. TSC is 
one of the medical conditions most strongly associated with autism and autism 
spectrum disorders. As a result, TSC has become a powerful model system to 
improve our understanding of autism in the context of TSC. For the purpose of 
this review, we did, however, not want to focus on autism spectrum disorders over 
and above the vast range of other neuropsychiatric difficulties that may be seen in 
addition to or instead of autism. Table 3.1 shows some of the most common 
problems reported by families and observed by clinicians, indicating the multiple 
levels of difficulties, and providing a summary of rates across difficulties (Leclezio 
and de Vries, 2015). Even though the majority of individuals with TSC will have 
neuropsychiatric problems across the lifespan, the range and variability seen has 
led to a number of clinical and research challenges. Below, we outline some of 
the key challenges, before proposing steps towards an improved understanding 
of TSC-associated neuropsychiatric disorders (TAND). 
 
Table 3.1. Multiple levels of TSC-Associated Neuropsychiatric Disorders (TAND) and reported 
rates (Adapted from Leclezio and de Vries, 2015). 
 
TAND Levels of investigation Rates 
1. Behavioural 
 
 Anxiety   
 Depressed mood  
 Overactivity, restlessness and impulsivity  








 Temper tantrums    
 Self-injury    
 Social-communication difficulties (including poor eye contact, repetitive and ritualistic 
behaviours, speech & language delay) 
 Sleep    
 
The significant variability in rates of behavioural difficulties may be explained by the differential rates 









Autism Spectrum Disorders    
 
The variability in these rates can be explained by the definition of ASD being used (classic autism 
versus autism spectrum disorders), the methodology employed (clinic based studies versus 
population based) and the level of intellectual ability of participants.  
 
 Attention Deficit Hyperactivity Disorder    
 
The prevalence of ADHD in TSC is as high as 50% in all individuals with TSC, and ~30% in those 
with normal IQ. 
 
 Mood Disorders 





















 Normal intellectual ability  
 Mild-moderate intellectual disability  
 Severe-Profound intellectual disability  
 
The majority of individuals with TSC (~70%) will have intellectual ability that falls on a normal 
distribution similar to that of the general population except that the mean IQ score is shifted 


















Rating scale measures suggest that at least 30% of children with TSC who have normal intellectual 
ability are at high risk of specific academic difficulties or learning disorders. Recent results from the 
TOSCA study showed that 332/682 (48.7%) of individuals with TSC had academic difficulties (de 






 Attentional deficits (sustained attention, dual tasking) 
 Memory deficits 
 Complex visuospatial deficits 
 Executive deficits (planning, set shifting, sequencing, verbal fluency) 
 Specific Language deficits  
 
The rates reported above are all based on performance of children and adults with normal intellectual 
ability. Recent result from the TOSCA study revealed neuropsychological deficits (performance <5
th
 













 Family stress 
 Sibling difficulties 
 Peer relationship difficulties 
 





Many biological factors may play a potential role in the bio-psycho-social presentation of an individual with 
TSC. Epilepsy, Anti-epilepsy medication, subependymal giant cell astrocytomas (SEGA), and renal failure 
have a strong correlation with TAND, and should be considered, particularly where there is a sudden change 





3.3 The Assessment and Management Gap of TAND 
 
One of the first challenges surrounding the neuropsychiatric difficulties of TSC is 
a global lack of assessment for these problems. In a survey of members of the 
United Kingdom Tuberous Sclerosis Association in 2010, only 18% of families 
surveyed had ever received any of the evaluations or treatments recommended in 
the 2005 TSC guidelines (de Vries et al., 2005; de Vries et al., 2015a). Similarly, 
in the international TuberOus SClerosis registry to increase disease Awareness 
(TOSCA) natural history study that includes over 2,000 patients from 31 countries 
(Kingswood et al., 2017), fewer than 40% of patients had ever had an intellectual 
ability assessment, and no data were available to determine whether the majority 
of patients had ever been assessed for autism spectrum disorder, ADHD, anxiety 
disorders or depression (de Vries et al., 2015a).  Given that more than 90% of all 
individuals with TSC are likely to have some of these challenges, the ‘assessment 
and treatment gap’ (the difference between clinical need and services provided) is 
therefore in excess of 70% (de Vries et al., 2015a). This means that most people 
with TSC receive good physical evaluation and care, but only a small proportion 
ever receive good quality neuropsychiatric and neurodevelopmental assessment 
and support. 
 
At the 2012 International TSC consensus conference, the neuropsychiatry panel 
expressed concern about the enormous treatment gap. The Panel commented 
that the ‘treatment gaps’ observed in TSC were similar to those observed in the 
Human Immunodeficiency Virus (HIV) community, where there used to be an 
overemphasis on physical treatment of HIV-positive individuals without 
consideration of the major neurocognitive and neuropsychiatric features of HIV 
(Antinori et al., 2007). The HIV community introduced the concept of HAND (HIV-
Associated Neurocognitive Disorders) as a strategy to raise awareness of such 
concerns. Inspired by the success of HAND, the term TAND (TSC-Associated 
Neuropsychiatric Disorders) was coined (de Vries et al., 2015a). Given that an 
individual’s TAND profile may change over time, the neuropsychiatry panel 
recommended that all individuals with TSC should be screened for TAND at least 
annually (Krueger et al., 2013; de Vries et al., 2015a). In order to facilitate the 
screening process, a TAND Checklist was developed to guide healthcare teams 
in a systematic enquiry across the levels of neuropsychiatric investigation 
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required in TSC (de Vries et al., 2015a; Leclezio et al., 2015).  
 
Leclezio et al. (2015) conducted pilot validation of the TAND Checklist and found 
that it showed good content validity, very good to excellent internal consistency, 
and strong correlations with external validation tools suggesting good external 
validity.  Overall, the pilot validation suggested that the TAND Checklist could 
provide a useful research tool and screening measure in clinical settings.  
 
The TAND Checklist is used in TSC clinics in various countries and has to date 
been translated into 2 other languages (Dutch and Swedish) and is in the process 
of being translated into German, French, Spanish, Portuguese, Hebrew, Mandarin 
and Afrikaans. A free, downloadable version of the TAND Checklist can be found 
at http://dx.doi.org/10.1016/j.pediatrneurol.2014.10.004.  
 
3.4 Perceived Uniqueness of TAND Profiles 
 
A second challenge for TAND is the perceived ‘uniqueness’ of individual TAND 
profiles. Table 3.1 summarised the group-based findings, but at an individual 
level, almost any combination of TAND characteristics can be seen. To date there 
are no obvious clinical indications of natural clustering of the components of 
TAND (de Vries, 2010a), and each individual appears to present with their very 
own unique profile. On the one hand it seems appropriate to advocate a 
‘personalised medicine’ approach, recognising each individual’s unique profile or 
TAND ‘signature’. On the other hand, this becomes a clinically very complex task 
that may be beyond the expertise of the majority of clinical teams. During the pilot 
validation of the TAND Checklist, Leclezio et al. (2015) gathered data from 20 
South African participants on behavioural difficulties across the lifespan. Figure 
3.1 shows a graphic representation of the behavioural items from the TAND 
Checklist data of these 20 participants. Behavioural problems, such as 
aggression, anxiety or self-injury, are indicated as either present (black) or absent 
(white). At first glance (Figure 3.1, Panel A) no obvious pattern of behavioural 
challenges was observed across participants. On closer inspection (Figure 3.1, 
Panel B), when the same data were rearranged and subjects were grouped 
based on the number and clustering of behavioural problems, it looks as though 
some grouping or clustering may be present. For instance, there may be a highly 
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affected group (mostly black boxes) and a mostly mildly affected group (mostly 
white boxes) of individuals. In between, there may be a subset of individuals with 
prominent ADHD-related (attentional) difficulties, and a group with ASD-related 
(social-communication) problems but less prominent attention-related difficulties. 
Visual inspection also suggests that there may be a group of individuals with 
prominent mood swings, aggression and tantrums, independent of other 
behavioural symptoms. It is at present unknown whether data reduction methods 
could reduce TAND variables sufficiently to a manageable number of segmented 
profiles. A small enough number of TAND clusters (perhaps fewer than 10) that 
have reasonable face validity could streamline early identification of profiles, 
ascertain clinical needs, and inform management options. 
 
Panel A  
 
Panel B  
 
 
Figure 3.1. The variability of TSC-Associated Neuropsychiatric Disorders (TAND). The figure 
shows the pattern of lifetime behavioural problems across a group of 20 individuals with TSC 
(used with permission from Leclezio et al., 2015). Each column represents one individual and 
each row represents a specific behavioural problem. Black box = abnormal; white box = no 
abnormality reported. Data are first presented in the order of assessment in the study (Panel A) 
and appear random without any obvious patterns. In Panel B data were rearranged and subjects 
were grouped based on the number and clustering of behavioural problems, with results providing 







3. 5 Treatment Paralysis in TAND 
 
As raised earlier, the perceived uniqueness of each individual’s TAND profile 
clearly points to the need for a personalised approach to evaluation and 
treatment. However, the vastness of possibilities may seem overwhelming to 
families, may make signposting to the most relevant services very challenging, 
and may require numerous highly-skilled professionals to assess and treat the 
individual, thus making the process either very complex or prohibitively 
expensive. Many clinicians who are experts in TSC do not feel they have the skills 
to assess and treat TAND. Conversely many neurodevelopmental and mental 
health experts do not feel that they have sufficient knowledge of TSC to lead 
assessment and treatment of those with the disorder. Together, this has very 
much led to what we refer to here as ‘treatment paralysis’. Early results from the 
TOSCA natural history study suggest that treatment paralysis may be real in TSC. 
Baseline TAND data from the first 2093 patients in the TOSCA study showed an 
average age of diagnosis for autism spectrum disorders in TSC of 7 years 7 
months (de Vries et al., 2015a). It is likely that expert clinicians over-emphasised 
assessment and treatment of physical manifestations (perhaps particularly 
epilepsy) and that the very late diagnosis of ASD was attributable to diagnostic 
overshadowing or treatment paralysis. Another example comes from an earlier 
study of attention difficulties and ADHD in children with TSC where 11 out of 20 
children in a research study met criteria for ADHD, but only 1 had ever been 
diagnosed and treated for ADHD (de Vries, Gardiner & Bolton, 2009). Needless to 
say, increased awareness of TAND should lead to improved assessment and 
treatment. The potential identification of natural clusters of TAND difficulties 
should further reduce the sense of diagnostic overwhelmedness and treatment 
paralysis of clinical teams.  
 
3.6 Potential next steps to improve our understanding of TAND 
 
There is no doubt that the neuropsychiatric disorders seen in TSC are some of 
the top concerns for families and have an enormous impact on quality of life for all 
who live with the condition. As outlined above, there is currently a large TAND 
‘treatment/identification gap’, each individual appears to present with their own 
unique profile of TAND, and clinicians are paralyzed by the multi-dimensionality of 
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TAND and its management and treatment options. In response to the above, the 
2012 TSC surveillance and management guidelines now recommend annual 
screening of TAND (Northrup et al., 2013) and a TAND Checklist was developed 
(de Vries et al., 2015a) and piloted (Leclezio et al., 2015). The hope is that 
coining of the term TAND, development of a TAND Checklist and inclusion of 
TAND in the management guidelines will improve awareness of the need to 
assess everyone with TSC for neuropsychiatric difficulties. 
 
As a next step, the evaluation and treatment of TAND may benefit from the 
search for ʻnatural clustersʼ – groups of neuropsychiatric manifestations across 
multiple levels - that could reduce the infinite and unique patterns observed into a 
small number of ʻTAND clustersʼ. Machine-based pattern recognition techniques 
have been used across a range of animal models and humans to reduce the 
multi-dimensionality of behavioural characteristics to generate new clusters (Geng 
et al., 2003; Wulffaert et al., 2009; Budaev, 2010; Meager et al., 2012). For 
example, Geng and colleagues studied the complex and multidimensional 
behavioural phenotypes of the nematode C. elegans. Multivariate data analysis 
was used to reduce the multi-dimensionality of data and to assess in a 
quantitative way the similarities between different behavioural phenotypes. Two 
hundred and fifty three (253) parameters were reduced into 39 features. These 
features classified into an optimal number of 6 clusters. Interestingly, the 
phenotypic clusters generated mapped well onto the underlying molecular defects 
of the different models (Geng et al., 2003). In 2012 Meager and colleagues 
examined the behavioural phenotype of wild and hatchery-reared Atlantic cod and 
used principal component analysis (PCA) to reduce the multi-dimensionality of the 
data and factor analysis (FA) to generate clusters rather than one-dimensional 
behavioural phenotyping methods. They were able to identify 8 behavioural 
clusters with behavioural phenotypes distinct in wild and hatchery-reared fish. 
Here the interesting observation was that there was a distinct phenotype in the 
wild cod not seen in the hatchery-reared animals. In a study of the behavioural 
phenotype of humans with Cornelia de Lange Syndrome (CdLS), categorical PCA 
was used as a tool to reduce data and to describe relationships between a large 
number of behavioural variables (Wulffaert et al., 2009). In their study, the 
methodology allowed them new insights into the relationships between physical 
and behavioural characteristics and into genotype-phenotype correlations. Taking 
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together the examples from nematode, fish, and humans with a specific genetic 
disorder, we suggest that reducing the multi-dimensionality of neuropsychiatric 
manifestations seen in TSC through various multivariate data analysis techniques 
may lead to identification of natural TAND clusters. Age and gender can be added 
into these analyses, thus allowing for the dynamic nature of the developmental 
needs of individuals with TAND. It would be of great significance to identify a 
small number of clusters that could help to reduce and make manageable the 
complexity of TAND.  
 
After identification of TAND clusters, a prioritisation exercise with TSC community 
stakeholders to identify TAND clusters of greatest concern will be helpful. It will be 
important to check with individuals, families and carers whether these newly 
generated ‘TAND clusters’ make sense to them and have face validity. This will 
ensure that statistical research remains embedded in real world needs. 
 
Priority TAND clusters can then be selected to generate a toolkit of treatment 
options. In various neurodevelopmental disorders such as ADHD and autism, and 
mental health disorders such as anxiety and depressive disorders, evidence-
based guidelines for treatment exist. It is best practice to develop clinical 
guidelines and/or toolkits in partnership with families and individuals affected by a 
particular condition. In the UK, for instance, the National Autistic Society led in the 
development of the National Autism Plan for Children (NAPC) and the NICE 
guidelines for assessment and treatment of autism (NAS, 2003; NICE 2011). In 
recent years the concept of community-based participatory research has 
developed a formal framework for participation of ʻusersʼ of research findings to 
ensure that what is done in an academic/laboratory-based setting has a high 
likelihood of being translated into real benefits for real people in the real world 
(Wallerstein and Duran, 2006). Excellent evidence-based guidelines that currently 
exist, such as the NICE guidelines mentioned above, alongside other tried and 
tested resources could potentially be incorporated into a toolkit for TSC clinical 
teams. An ideal toolkit should contain evidence-based guidelines and practical 





There is growing recognition of the burden of TAND, and the importance to 
assess and treat individuals with TAND. We hope that the coining of the term 
TAND, recommending annual TAND screening and development of the TAND 
Checklist will help to reduce the assessment/treatment gap that currently exists. 
We propose that future research should focus on reducing the complexity of 
TAND by searching for natural TAND clusters and thereby reducing the 
overwhelming sense of ‘uniqueness’ of individual TAND profiles. If our hypothesis 
proves to be correct and natural TAND clusters do exist, this may inform further 
research into the mechanisms and molecular treatments of TAND across human 
and animal models. For instance, if TAND clusters were identified it would be very 
interesting to see if any correlated to particular genotypes, given the emerging 
genotype-phenotype correlations described by van Eeghen et al. (2012) and 
Wong et al. (2015). Finally, we propose that the development of a simple toolkit of 
evidence-based guidelines, information and tips to families and clinical teams, 
could go some way to reducing the treatment paralysis surrounding TAND.  
 
 
3.8 Chapter Summary 
 
Tuberous Sclerosis Complex (TSC) is associated with many learning, 
behavioural, neurodevelopmental and psychiatric difficulties. Over 90% of those 
with TSC will have some of these concerns, yet typically no more than 20% 
receive support and treatment. This paper provides an overview of TSC-
Associated Neuropsychiatric Disorders (TAND), explores barriers to identification 
and management of TAND, and proposes possible next steps to improve 
assessment and treatment of TAND. The chapter combined a brief review of the 
multiple levels of TAND with a conceptual analysis of barriers and potential 
facilitators to assessment and intervention for TAND. Results suggest that the 
perceived uniqueness of TAND leads to treatment paralysis for most healthcare 
professionals, thus explaining the assessment and treatment gap seen for TAND. 
This may in part be due to the multi-dimensionality of TAND, and in part due to 
lack of access to clear, useful and evidence-based resources for TAND. 
Identification of natural TAND clusters through machine-based learning and data 
reduction methodologies may yield a manageable number of natural groups of 
TSC-related neuropsychiatric problems, for which a basic ‘toolkit’ of evidence-
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based interventions could be developed. Families and clinicians will benefit from a 
toolkit of tried and tested resources and evidence-based information to guide 
further investigation and management of TAND. Even though individuals will have 
unique TAND profiles, there may be key natural TAND Clusters (combinations of 
behaviours across multi-dimensional levels) that will simplify and improve access 























IDENTIFICATION OF NATURAL CLUSTERS OF TSC-
ASSOCIATED NEUROPSYCHIATRIC DISORDERS – A PILOT 
FEASIBILITY STUDY 
 
Leclezio, L., Gardner-Lubbe, S., and de Vries, P.J. (2017). 





Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder 
caused by mutations in either of two genes, the TSC1 gene on chromosome 9q34 
(Povey et al., 1994; van Slegtenhorst et al., 1997) or the TSC2 gene on 
chromosome 16p13.3. (European Chromosome 16 Consortium, 1993; Povey et 
al., 1994). Up to 75% of cases occur as spontaneous mutations and the 
remaining ~25% are familial (Kingswood and de Vries, 2015). The birth incidence 
of TSC is estimated to be 1 in 5,800 newborn babies (Osborne et al., 1991; 
O’Callaghan et al., 1998; Krueger et al., 2013) with an equal male/female 
distribution. TSC is a multi-system disorder and can affect nearly any organ 
system, with most common physical manifestations being benign tumours in the 
central nervous system, skin, kidneys, heart, and lungs. There is significant 
phenotypic variability in the number and severity of physical features of the 
disorder (Povey et al., 1994; Curatolo et al., 2015). TSC has an age-related 
expression pattern with certain features more prevalent during infancy and 
childhood, and others more likely to manifest during adolescence or in adulthood 
(Curatolo et al., 2008). Management and coordination of medical specialist care is 
crucial across the lifespan to limit morbidity and mortality in individuals with TSC 
(Krueger et al., 2013; Curatolo et al., 2015). 
 
Tuberous Sclerosis is associated with a vast and variable range of TSC-
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Associated Neuropsychiatric Disorders (TAND) that can present in infancy, 
childhood, adolescence or adulthood. The multi-level manifestations of TAND 
include behavioural, psychiatric, intellectual, academic, neuropsychological and 
psycho-social difficulties. Table 4.1 contains the various aspects of TAND, 
indicating the specific variables and domains examined in this pilot study.  
 
Table 4.1. Components of TSC-Associated Neuropsychiatric Disorders (* indicates items included 
in this pilot study) 
 
 
In a recent conceptual review of TAND, three clinical and research challenges 
were identified (Leclezio and de Vries, 2015). The first challenge is a so-called 
‘assessment and management gap’ of TAND. Despite the fact that the lifetime 
prevalence of TAND is in the region of 90% (de Vries et al., 2015a), there 
appears to be a global lack of assessment for these problems. A study conducted 
in the United Kingdom in 2010 showed that only 18% of all families had ever 
received any of the evaluations or treatments recommended in the 2005 TSC 
guidelines (de Vries et al., 2005; de Vries et al., 2015a). Interestingly, in the 
international TuberOus Sclerosis registry to inCrease disease Awareness 
(TOSCA) study of over 2000 patients from 31 countries, fewer than 40% of 
patients had ever had an intellectual ability assessment, and very high rates of 
missing TAND data were reported (Kingswood et al., 2017). These findings 
suggested that, even in expert TSC centres, TAND are likely to be under-
 




























































































identified and under-treated.  
 
In order to raise awareness of these neuropsychiatric difficulties in TSC and 
encourage assessment and screening, the term ‘TAND’ was coined (de Vries et 
al., 2015a) and the current TSC surveillance and management guidelines 
(Krueger et al., 2013) recommend annual screening for TAND. To guide 
healthcare teams in a systematic enquiry of TAND, a TAND Checklist was 
developed and pilot validated (de Vries et al., 2015a; Leclezio et al., 2015). 
Results from this pilot study suggested the TAND Checklist to be a good 
screening tool to identify possible neuropsychiatric difficulties (Leclezio et al., 
2015). A free downloadable English version of the TAND Checklist is available 
(de Vries et al., 2015a) and a global programme to translate the TAND Checklist 
is currently underway. 
 
The second challenge for TAND described by Leclezio & de Vries is the 
perceived “uniqueness” of individual TAND profiles (Leclezio and de Vries, 2015). 
It appears that, at an individual level, each person has their own set and 
combination of TAND features with no two individuals presenting the same TAND 
“signature”. This uniqueness poses significant challenges for diagnostic work-up, 
psycho-education and intervention planning, particularly given the rarity of TSC 
and the multi-level nature of TAND. Leclezio and de Vries commented that, to 
date, there have been no obvious indications of natural clustering, that is, natural, 
predictable grouping of specific neuropsychiatric characteristics across levels of 
TAND (Leclezio and de Vries, 2015). The authors suggested that the potential 
identification of such natural TAND clusters may be a powerful strategy to 
manage the assessment/management gap, and to reduce the third challenge, 
referred to as ‘treatment paralysis’ (Leclezio and de Vries, 2015).  
 
In this study, we examined the feasibility of using multivariate data analysis 
techniques as a novel strategy in TSC to reduce the multidimensionality of data, 
in search of possible natural TAND clusters. We proposed that data reduction 
may identify a small number of TAND clusters that could help to reduce and make 
manageable the complexity of TAND. This strategy may be helpful both for the 
detection of aetiological subgroups or subtypes in TSC, and for a more 
personalised management and treatment approach in clinical settings. Our aims 
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were to investigate the practicability of identifying natural TAND clusters and to 





Participants for this study were part of the ‘Pilot Validation of the Tuberous 
Sclerosis-Associated Neuropsychiatric Disorders (TAND) Checklist’ study 
(Leclezio et al., 2015). Twenty study participants from Cape Town, South Africa, 
were recruited through the Red Cross War Memorial Children’s Hospital TSC 
Clinic. Thirty-seven study participants from Australia were recruited via the 
Australasian Tuberous Sclerosis Society. To be eligible, participants had to meet 
criteria for TSC (Northrup et al., 2013) and had to have a parent or caregiver who 
could complete the TAND Checklist in English. The pilot data deliberately 
included participants with a wide age and ability range.    
 
4.2.2 Procedures 
The TAND Checklist was administered to parents and caregivers of individuals 
with TSC by one of the researchers (LL or PJdV). The TAND Checklist follows the 
neuropsychiatric levels of investigation outlined previously (de Vries et al, 2015a) 
and contains the following 12 sections: 1. Basic developmental milestones; 2. 
Current level of functioning; 3. Behavioural concerns; 4. Psychiatric disorders 
diagnosed; 5. Intellectual ability; 6. Academic skills; 7. Neuropsychological skills; 
8. Psychosocial functioning; 9. Parent, caregiver, or self-rating of the impact of 
TAND; 10, Prioritisation list; 11. Additional concerns; and 12. Healthcare 
professional rating of the impact of TAND. Questions require simple YES or NO 
responses to most sections (de Vries et al, 2015a). 
 
4.2.3 Data Analysis  
All analyses were performed with the R software package (R Core Team, 2016). 
The following sections of the TAND Checklist were included in the analysis: 
Section 3, behavioural challenges (19 questions/variables); Section 5, academic 
skills (4 variables); and Section 7, neuropsychological skills (6 variables). Given 
that all variables were binary (Yes/No), model-based clustering assuming an 
underlying Gaussian distribution was not considered suitable. Instead, the mean 
57  
squared contingency coefficient (Cramer, 1999) was used to compute a 
correlation matrix for the 29 variables selected from the TAND Checklist. Where 
missing values were present, these were omitted pairwise in correlation 
computations. 
 
Several clustering solutions were compared. Hierarchical clustering methods 
provide a clustering tree visually representing the merging of TAND variables and 
suggesting a suitable number of clusters. Complete linkage, average linkage, 
WARD’s method and McQuitty’s methods were applied with the hclust() R 
function. Although hierarchical clustering has often been used with great success, 
the algorithm is fairly naïve and some more recent methods in the R package 
cluster (Maechler et al., 2016) were therefore also investigated. PAM (partitioning 
around mediods) is an extension of the popular k-means clustering method. K-
means could not be applied given that it required a numerical data matrix rather 
than a dissimilarity matrix based on the square contingency coefficient correlation 
matrix. The FANNY (fuzzy clustering) method allocates a probability for belonging 
to each cluster rather than simply allocating each item to a single cluster. DIANA 
(divisive analysis), also a hierarchical clustering method, was also used. In 
contrast to the other methods where larger clusters are formed by merging 
smaller clusters, this method forms smaller clusters by dividing larger clusters. 
 
After a suitable clustering solution was obtained, exploratory factor analysis was 
employed with the function fa() from the R package psych (Revelle, 2016). The 
factor analysis was also performed on the means squared contingency coefficient 
correlation matrix. All the different options of factor extraction and rotation 
available in the fa() R function were investigated. These combinations were 
applied to solutions with between four and seven factors. In order to find the 
factor solution that best matched the cluster analysis solution, the Tucker index of 
factor congruence (Lorenzo-Seva and Ten Berge, 2006) was used. To summarise 
the congruence from the matrix of indices, the matrix was optimally rotated to the 
indicator matrix with Orthogonal Procrustes Analysis, and the differences in trace 
were computed. For algebraic details, see Appendix D. 
 
Finally, we set out to compare the data-driven cluster solutions with the 




4.3 Results  
 
4.3.1 Cluster Analysis 
Cluster analysis showed a six cluster solution to be optimal. Hierarchical 
clustering with WARD’s method produced the most suitable six cluster solution. A 
dendrogram of the WARD cluster analysis shows detail of the natural clustering of 
the TAND variables examined (Figure 4.1). A heatmap of the WARD cluster 
analysis results (Figure 4.2) shows TAND variables of study participants across 








Figure 4.2. WARD’s cluster analysis results show TAND variables across in the six clusters (Y-
axis) for all study participants (X-axis) in a heatmap.  
RED = Yes response to TAND Checklist item 
GREEN = No response to TAND Checklist item 
WHITE = Missing item 
 
As shown in the dendrogram, the first cluster included difficulties with reading, 
spelling, writing, and mathematics, suggesting a natural ‘Scholastic’ cluster. The 
second cluster included delayed language, unusual eye contact, repetitive 
behaviours, unusual use of language, self-injurious behaviours, difficulties 
associated with eating (or unusual food preferences), and visio-spatial difficulties. 
These characteristics suggested a natural ‘Autism Spectrum Disorder-like‘ cluster. 
The third cluster included aggressive outbursts, mood swings, and temper 
tantrums, suggesting a natural ‘Dysregulated Behaviour’ cluster.  The fourth 
included memory problems, dual-task deficits, executive deficits, daily life 
attention difficulties, neuropsychological attention difficulties as well as 
disorientation and peer difficulties. These suggested a natural 
‘Neuropsychological’ cluster. The fifth cluster included overactivity, restlessness, 
impulsivity and inflexibility, suggesting a ‘Hyperactive/Impulsive’ cluster. The sixth 
cluster included anxiety, depression, extreme shyness and sleep difficulties, 













































































































































































































































































































































































































The heatmap (Figure 4.2) shows these 6 clusters across individual participants in 
the study. Results showed a group of individuals who didn’t fall into any clusters 
(not affected by set variables), some that fell into 1 or 2 clusters, and a group of 
individuals affected across most or all clusters.  
 
4.3.2 Exploratory Factor Analysis  
As shown in Table 4.2 the factor analysis solution which most closely matched 
WARD’s hierarchical cluster analysis was the least squares extraction method 
with Bentler’s T orthogonal rotation (Benedik et al., 1977) which also produced six 
factors. The six factors also mapped onto clinical constructs linked to scholastic 
skills, ASD, dysregulated behaviour, neuropsychological deficits, 
hyperactive/impulsive behaviours and a mixed/mood factor. 
 




4.3.3 Comparison of WARD’s cluster analysis and Factor analysis 
Figure 4.3 shows the similarities and differences between cluster analysis and 
exploratory factor analysis. In the “Scholastic” natural TAND cluster there was a 
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perfect match of identified variables (spelling, reading, mathematics, and writing) 
between cluster and factor analysis methods. In the second “ASD-like” natural 
TAND cluster, factor analysis included two additional characteristics, peer 
difficulty and disorientation, but other items were identical. In the “Dysregulated 
Behaviour” natural TAND cluster, factor analysis added anxiety behaviours to the 
other three variables (temper tantrums, mood swings and aggressive outbursts). 
Factor analysis identified an attentional-executive “Neuropsychological” natural 
TAND cluster, while cluster analysis also included memory difficulties, peer 
difficulties, and disorientation in this cluster. The “Hyperactive/impulsive” natural 
TAND cluster showed a perfect match between cluster and factor analysis 
methods (over-activity, restlessness, impulsivity, and inflexibility). In the 
“Mood/Mixed” natural TAND cluster, factor analysis combined depressed mood, 
sleep problems, extreme shyness and memory difficulties, whereas cluster 
analysis included anxiety in the “Mood” cluster, and clustered memory difficulties 




Figure 4.3. Comparison of WARD’s cluster analysis and exploratory factor analysis shows the 






The complexity and apparent individual ‘uniqueness’ of TSC-associated 
neuropsychiatric (TAND) profiles in people with TSC has meant that most people 
never received appropriate assessment or intervention for the range of 
neuropsychiatric manifestations that they may have had. We proposed that 
identification of relatively small number of natural TAND clusters might improve 
assessment and intervention for individuals with TAND. In this first ever study to 
investigate the occurrence of natural TAND clusters, we explored the practicability 
of applying data-driven strategies using the TAND Checklist (de Vries et al., 
2015a). Using data across 29 variables from 56 unrelated individuals with TSC, 
the multivariate cluster analysis and factor analysis methods applied generated 6 
natural TAND clusters with clinically-meaningful face validity.  
 
Based on the existing TSC literature, the Scholastic cluster maps very well onto 
the high rates of academic difficulties and learning disorders seen in TSC 
(Joinson et al., 2003; de Vries, 2010a). The Hyperactive/Impulsive cluster 
represents another commonly reported set of difficulties, with very high rates of 
ADHD reported in TSC (Prather and de Vries, 2004; de Vries, 2010a). TSC is one 
of the medical conditions most commonly associated with ASD (Bolton et al., 
2002; de Vries, 2010), and the ASD-like cluster therefore seems intuitively 
meaningful. Many individuals with TSC, particularly those with normal intellectual 
ability have high rates of neuropsychological deficits in areas such as attentional-
executive skills and memory (Prather and de Vries, 2004; Ridler et al., 2007; de 
Vries et al., 2009; de Vries, 2010a), so the natural clustering of 
neuropsychological deficits therefore also appears meaningful. It was interesting 
to observe the emergence of a cluster of behavioural difficulties including 
aggression, mood swings and temper tantrums. We suggest that this may point 
towards the existence of a ‘Dysregulated Behaviour’ cluster in TSC. The 
manifestations of anger, temper tantrums and mood swings are certainly clinically 
common and highly problematic to families, and correlate with other behaviours 
that challenge (Prather and de Vries, 2004; Eden et al., 2014), suggesting this to 
be a potentially important natural TAND cluster to explore further. Whilst anxiety 
and depressed mood is very common in TSC (de Vries, 2010a), the Mood/Mixed 
cluster identified requires further exploration. 
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The second aim of this study was to identify suitable methods of data reduction. 
In this pilot study, WARD’s hierarchical cluster analysis produced the most 
appropriate six cluster solution with good clinical face-validity. After identification 
of the six cluster solution, exploratory factor analysis was applied, and rendered 
very similar results to those generated through cluster analysis. The comparability 
between the two methods points towards robustness in the natural clustering of 
the TAND variables examined here. The minor differences between the cluster 
and factor analysis, however, suggest that it would be prudent to combine these 
methods in next-step examination of TAND.  
 
4.4.1 Limitations  
 
Firstly, we are conscious that there are many potential limitations to these pilot 
findings, and we remain cautious not to over-interpret results based on the small 
sample of participants presented here. However, we were encouraged to see the 
emergence of six potential natural TAND clusters from the data. Replication and 
extension in a larger sample should produce more definitive findings. Secondly, 
the TAND Checklist was used here to identify potential natural TAND clusters in 
this pilot study. No other sources of information that may be relevant in cluster 
analysis or factor analysis, such as clinical evaluations or neuropsychological 
assessments were included. We acknowledge that it is therefore theoretically 
possible that other clusters and factors may be identified using different kinds of 
multi-level data. However, we specifically wanted to use the TAND Checklist here, 
given that it is simple, yet systematic, and freely available. As reported earlier, 
pilot validation of the TAND Checklist (Leclezio et al., 2015) indicated that the 
TAND Checklist was a valid tool in extrapolating multi-level neuropsychiatric 
manifestations in TSC. Thirdly, we acknowledge that some participants were 
recruited through a parent organisation, which might have introduced biases. 
However, the purpose here was an exploratory methodological evaluation, and 
the clinical significance of findings should therefore be deferred until replication 







The need for identifying natural TAND clusters to reduce the perceived 
overwhelming uniqueness of TAND profiles has gained urgency with the parallel 
development of tools such as the TAND Checklist for screening neuropsychiatric 
manifestations in TSC. This pilot feasibility study was the first of its kind to apply 
multivariate data analysis techniques to identify natural TAND clusters. WARD 
hierarchical cluster analysis rendered six clinically-meaningful clusters and factor 
analysis produced similar results. Larger-scale replication and extension is now 
required. Factor analysis can potentially also be used to generate ‘factor scores’ 
for each individual on a specific factor, thus leading to a ‘personalised’ 
quantification of an individual’s natural TAND cluster profile. We hope that 
successful next steps may also facilitate the development of resources, guidelines 
and training to improve the assessment and treatment of TAND in individuals with 
TSC.  
 
4.6 Chapter Summary 
 
Tuberous Sclerosis Complex (TSC) is a genetic disorder with multi-system 
involvement. The lifetime prevalence of TSC-Associated Neuropsychiatric 
Disorders (TAND) is in the region of 90% in an apparently unique, individual 
pattern. This ‘uniqueness’ poses significant challenges for diagnosis, psycho-
education, and intervention planning. To date, no studies have explored whether 
there may be natural clusters of TAND. The purpose of this pilot study was (a) to 
investigate the practicability of identifying natural TAND clusters, and (b) to 
identify appropriate multivariate data analysis techniques for larger-scale studies. 
TAND Checklist data were collected from 56 individuals with a clinical diagnosis 
of TSC (n= 20 from South Africa; n = 36 from Australia). Using R, the open-
source statistical platform, mean squared contingency coefficients were 
calculated to produce a correlation matrix, and various cluster analyses and 
exploratory factory analysis (EFA) were examined. WARD’s method rendered six 
TAND clusters with good face validity and significant convergence with a six-
factor EFA solution. The data-driven strategies identified a ‘Scholastic’ cluster of 
TAND manifestations, an ‘ASD-like’ cluster, a ‘Dysregulated Behaviour’ cluster, a 
‘Neuropsychological’ cluster, a ‘Hyperactive/Impulsive’ cluster, and a 
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‘Mixed/Mood’ cluster. These pilot results suggest that a combination of cluster 
analysis and exploratory factor analysis methods may be able to identify clinically-
meaningful natural TAND clusters. Findings require replication and expansion in 
larger dataset, and could include quantification of cluster/factor scores at an 

























MULTIVARIATE DATA ANALYSIS IDENTIFIES NATURAL 
CLUSTERS OF TUBEROUS SCLEROSIS COMPLEX ASSOCIATED 





As illustrated in the previous chapters, each person with TSC appears to present 
with their own unique profile or ‘TAND signature’ with no two individuals 
presenting the same combination of TAND features (Leclezio and de Vries, 2016). 
We suggested that the complexity and perceived uniqueness of TAND profiles as 
a barrier to diagnostic work-up, psycho-education and intervention planning, and 
proposed that the identification of natural TAND clusters - predictable groupings of 
specific neuropsychiatric characteristics - may be a powerful strategy to reduce 
the perceived overwhelming uniqueness of individual TAND profiles and resulting 
treatment paralysis, and could lead to the development of a personalised 
approach to management and treatment of individuals with TSC in clinical 
settings.  
 
Machine-based data reduction methods have been used in humans to reduce the 
multi-dimensionality of behavioural characteristics to identify previously 
unrecognised clusters of behaviours. For example, in a study of the behavioural 
phenotype of humans with Cornelia de Lange Syndrome (CdLS), categorical 
principal component analysis (PCA) was used as a data reduction tool and to 
describe relationships between a large number of behavioural variables (Wulffaert 
et al., 2009). This methodology allowed for new insights into the relationships 
between physical and behavioural characteristics and into genotype-phenotype 
correlations. 
 
In a pilot feasibility study, Leclezio et al. (2017) set out to examine the viability of 
using multivariate data analysis techniques as a novel strategy in TSC to search 
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for possible natural TAND clusters. Cluster analysis of 29 variables in 56 
individuals rendered six natural TAND clusters with good face validity and 
significant convergence with a six-factor exploratory factor analysis solution 
(Leclezio et al., 2017). The natural TAND clusters identified included a ‘Scholastic’ 
cluster of TAND manifestations, an ‘ASD-like’ cluster, a ‘Dysregulated Behaviour’ 
cluster, a ‘Neuropsychological’ cluster, a ‘Hyperactive/Impulsive’ cluster, and a 
‘Mixed/Mood’ cluster. The pilot methodological study, however, had a small 
sample from only two centres (South Africa and Australia) and, whilst informative, 
therefore clearly required replication and expansion. Additional unanswered 
questions from this study included statistical robustness and internal consistency 
of the putative TAND clusters. 
 
In this study, our aim was to determine whether multi-dimensional TAND data 
could be reduced to clinically meaningful, natural TAND clusters in a much larger 
dataset. In addition, we set out to examine robustness and internal consistency of 





Participants for this study (n=453) were recruited from five global TSC clinics: 
Cincinnatti, USA (365 participants), Boston, USA (25 participants), Brussels, 
Belgium (25 participants), Dallas, USA (14 participants) and Leuven, Belgium (9 
participants). An additional n=16 participants were recruited through Tuberous 
Sclerosis International (TSCi). To be eligible, participants had to meet criteria for 
TSC (Roach et al., 1998, Krueger et al., 2013). The data deliberately included 
participants with a wide age and ability range. This study was conducted in 
compliance with the Declaration of Helsinki. The protocol was peer-reviewed in 
the Department of Psychiatry at the University of Cape Town and submitted for 
ethical approval by the Faculty of Health Sciences, Human Research Ethics 
Committee (Ethics Ref 340/2015). Additional study sites obtained ethical approval 
from their respective HREC/IRB bodies.   
 
5.2.2 Procedures 
The TAND Checklist was administered to parents and caregivers of individuals 
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with TSC by the resident TSC coordinator and/or treating physician. The TAND 
Checklist follows the neuropsychiatric levels of investigation outlined previously 
(de Vries et al., 2015a) and contains the following 12 sections: 1. Basic 
developmental milestones; 2. Current level of functioning; 3. Bahavioural 
concerns; 4. Psychiatric disorders diagnosed; 5. Intellectual ability; 6. Academic 
skills; 7. Neuropsychological skills; 8. Psychosocial functioning; 9. Parent, 
caregiver, or self-rating of the impact of TAND; 10, Prioritisation list; 11. Additional 
concerns; and 12. Healthcare professional rating of the impact of TAND. 
Questions require simple YES or NO responses to most sections. For a detail 
about TAND and the TAND Checklist, including a downloadable version of the 
Checklist, please see de Vries et al. (2015a). A copy of the TAND Checklist is 
also provided in the appendix of the thesis. 
 
5.2.3 Data Analysis 









STEP 1. Select TAND Checklist variables 
The following sections of the TAND Checklist were included in the analysis: 
Section 3, behavioural challenges (19 questions/variables); Section 5, academic 
skills (4 variables); and Section 7, neuropsychological skills (6 variables). This 
equated to 29 dichotomous TAND variables. Sections 1 and 2 were omitted as 
they refer to developmental milestones (section 1) and current level of functioning 
(section 2).  Section 4 addresses specific psychiatric diagnosis and section 6, 
Intellectual ability (3 options: normal ability, mild/moderate intellectual disability, 
severe/profound intellectual disability). These two sections were also excluded as 
they were not deemed appropriate in generating natural TAND clusters. Lastly, 
section 9 was also omitted as it refers to parent, caregiver, or self-rating of the 
impact of TAND (likert scale 1-10). 
 
STEP 2. Compute Correlation Matrix 
Mean squared contingency coefficient (Cramer, 1946) was used to compute a 
correlation matrix for the 29 binary variables selected from the TAND Checklist. 
Where missing values were present, these were omitted pairwise in correlation 
computations. 
 
STEP 3. Cluster Analysis 
Several clustering solutions were compared. Hierarchical clustering methods 
provide a clustering tree visually representing the merging of TAND variables and 
suggesting a suitable number of clusters. Complete linkage, average linkage, 
WARD’s method and McQuitty’s methods were applied with the hclust() R 
function. Although hierarchical clustering has often been used with great success, 
the algorithm is fairly naïve and some more recent methods in the R package 
cluster (R Core Team, 2016) were therefore also investigated. PAM (partitioning 
around mediods) is an extension of the popular k-means clustering method. K-
means could not be applied given that it required a numerical data matrix rather 
than a dissimilarity matrix based on the square contingency coefficient correlation 
matrix. Given that most variables were binary (Yes/No), model-based clustering 
assuming an underlying Gaussian distribution was not considered suitable. The 
FANNY (fuzzy clustering) method applied to the data allocates a probability for 
belonging to each cluster rather than simply allocating each item to a single 
cluster. DIANA (divisive analysis), also a hierarchical clustering method, was also 
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used. In contrast to the other methods where larger clusters are formed by 
merging smaller clusters, this method forms smaller clusters by dividing larger 
clusters. 
 
STEP 4. Bootstrapping  
Following cluster analysis, a bootstrap method was applied to assess the 
statistical robustness or stability of the clustering solution. In a bootstrap analysis, 
the ‘real world’ analysis is repeated a large number, say 1000 times, in the 
‘bootstrap world’. Having 1000 bootstrap samples provide the researcher with an 
indication of the variability in the analysis, should it be repeated several times. For 
a single bootstrap replicate, a sample of size 453 patients is obtained through 
random sampling with replacement from the observed sample of 453 patients. 
This means that some patients can appear more than once in the bootstrap 
sample whilst others do not appear at all. Based on the bootstrap sample of 
patients, a square contingency coefficient correlation matrix was computed and 
hierarchical cluster analysis with WARD’s method was performed. The number of 
clusters were fixed at 7 and a bootstrap replicate clustering solution was obtained. 
Repeating this process 1000 times, 1000 clustering solutions were obtained. In 
order to assess the robustness or stability of the original observed clustering 
solution, the number of times each pair of variables were clustered together was 
calculated. For a perfectly stable clustering solution with no random noise, two 
variables that were in the same cluster would have been expected to cluster 
together 1000 out of 1000 times (bootstrap value = 1) in the bootstrap replicates 
and two variables that belong to different clusters in the observed clustering 
solution would have clustered together 0 out of 1000 times (bootstrap value = 0) 
in the bootstrap replicate. In practice a stable solution would have items clustered 
together in the same cluster in the majority of bootstrap replicates and items not 
clustering together only occasionally in the same bootstrap cluster. 
 
STEP 5. Exploratory Factor Analysis 
After suitable clustering solutions were obtained and bootstrapping applied, 
exploratory factor analysis was employed with the function fa() from the R 
package psych (Revelle, 2016). The factor analysis was also performed on the 
mean squared contingency coefficient correlation matrix. All the different options 
of factor extraction and rotation available in the fa() R function were investigated. 
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These combinations were applied to solutions with between four and seven 
factors. In order to find the factor solution that best matched the cluster analysis 
solution, the Tucker index of factor congruence (Lorenzo-Seva and ten Berge, 
2006) was used. A perfect match would have a square matrix with 1 on the 
diagonal (indicating a perfect match) and 0 on the off-diagonal (indicating a 
complete mismatch). Changing the order of the rows or columns of this matrix 
also represents a perfect match with the inconsequential naming of the clusters in 
a different order. To ensure a unique congruence matrix, the computed pairwise 
congruence matrix is optimally rotated to the indicator matrix. Rotation is based on 
Orthogonal Procrustes Analysis and the overall congruence summarised by the 
sum of the diagonal values. For cases other than 6 factors, the congruence matrix 
is padded with zeros to obtain a square matrix before rotation. For algebraic 
details, see Appendix E. 
 
STEP 6. Test Internal Consistency 
Reliability analysis was used to test the internal consistency of the TAND 
variables comprised in both the clusters identified and factors generated.  
 
STEP 7. Compare Cluster Analysis findings with Exploratory Factor Analysis 
Results 
Finally, we set out to compare the data-driven cluster solutions with the 
exploratory factor analysis in order to examine similarities and differences of the 




5.3.1 Cluster Analysis 
Hierarchical clustering with WARD’s method produced a seven-cluster solution. A 
dendrogram of the WARD cluster analysis shows detail of the natural clustering of 





Figure 5.2. Dendrogram illustrating WARD’s cluster analysis method which rendered 7 natural 
TAND Clusters (n= 453) 
 
The first cluster included items on difficulties with mathematics, spelling, writing, 
and reading suggesting a natural ‘Scholastic’ cluster. The second cluster included 
items for memory difficulties, getting disorientated, attention difficulties at both a 
behavioural and neuropsychological level, difficulty with visuo-spatial tasks, dual-
task difficulties, and executive skills difficulties. These suggested a natural 
‘Neuropsychological’ cluster. The third cluster included extreme shyness, 
depressed mood, anxiety, and mood swings, suggesting a natural ‘Mood/Anxiety’ 
cluster. The fourth cluster grouped together inflexibility, unusual language 
(repeating words or phrases over and over again), repetitive behaviours, poor eye 
contact, and peer difficulties, suggesting Autism Spectrum Disorder (ASD)-like 
characteristics. The fifth cluster included aggressive outbursts, temper tantrums, 
self-injury, and absent or delayed onset of language. These characteristics were 
slightly mixed but overall supported a natural ‘Behavioural Dysregulation‘ cluster. 
The sixth cluster, suggesting a natural ‘Overactive/Impulsive’ cluster contained 












































































































































































biological items - difficulties with eating and sleep-related difficulties. We therefore 
refer to this as the ‘Eat/Sleep’ cluster.  
 
5.3.2 Bootstrapping  
Table 5.1 shows the bootstrapping results expressed as a proportion of times two 
items cluster together. The Scholastic cluster was very stable with all four items 
clustering together 100% of the time. A few other items showed bootstrapping 
values between 29% and 58% (Visuo-spatial skills, 58%; Dual-tasking, 29%; 
Executive Skills, 29%) in association with the scholastic items. All other items had 
bootstrap values < 20%. In the Neuropsychological cluster, items were stable with 
bootstrap values ranging from 100% (behavioural and neuropsychological 
attention difficulties; dual-tasking and executive skills), 92% (memory), 72% 
(disorientation), to 60% (visuo-spatial). Items in the Overactive/Impulsive cluster 
clustered together 100% of the time (overactive; restless) and 65% of the time 
included impulsivity. In the Mood/Anxiety cluster extreme shyness showed 
bootstrapping values between 42% and 91%; depressed mood between 49% and 
91%; anxiety between 51% and 97%, and mood swings between 42% and 51%. 
The fifth cluster, Dysregulated Behaviour, showed two items (temper tantrums 
and aggressive outbursts) that clustered together 100% of the time and two items  
(self-injury and delayed language) that showed very low bootstrapping values with 
aggression/temper tantrums (19% and 30%). The ASD-like cluster items ranged 
between 26% and 97%. The items showed bootstrapping values between 24% 
and 65% (inflexibility 24%-48%, poor eye contact 35% and 65%, peer difficulty 
31% - 65%) within this cluster. When considered alongside ASD-like cluster items, 
self-injury and delayed language clustered together 88% of the time and unusual 
language and repetitive behaviour 97%. These bootstrapping values were higher 
in the ASD-like cluster when compared with their bootstrapping scores obtained in 
the Dysregulated Behaviour cluster. The two items of the Eat/Sleep cluster, 
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Bflex 0.01 0.01 0.01 0.01 0.03 0.02 0.02 0.03 0.02 0.03 0.03 0.32 0.13 0.13 0.29 0.25 0.22 0.19 0.44 0.43 0.48 0.35 1.00 0.54 0.56 0.24 0.26 0.18 0.15 
Brep 0.08 0.08 0.08 0.07 p.14 0.02 0.02 0.03 0.01 0.01 0.01 0.17 0.11 0.11 0.10 0.01 0.00 0.00 0.30 0.30 0.42 0.58 0.54 1.00 0.97 0.65 0.64 0.14 0.05 
Bu.lang 0.07 0.07 0.07 0.06 0.13 0.03 0.03 0.03 0.01 0.01 0.01 0.18 0.11 0.11 0.11 0.01 0.00 0.00 0.32 0.32 0.43 0.57 0.56 0.97 1.00 0.62 0.62 0.14 0.05 
Blang 0.20 0.20 0.20 0.20 0.25 0.04 0.04 0.04 0.01 0.01 0.01 0.04 0.06 0.06 0.03 0.00 0.00 0.00 0.19 0.19 0.31 0.59 0.24 0.65 0.62 1.00 0.88 0.19 0.07 
Bs.inj 0.13 0.13 0.13 0.13 0.18 0.02 0.02 0.03 0.00 0.00 0.00 0.06 0.08 0.08 0.07 0.00 0.00 0.00 0.30 0.30 0.33 0.55 0.26 0.64 0.62 0.88 1.00 0.20 0.08 
Beat 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.03 0.03 0.17 0.09 0.10 0.22 0.13 0.02 0.01 0.01 0.22 0.22 0.47 0.38 0.18 0.14 0.14 0.19 0.20 1.00 0.78 
Bsleep 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.02 0.12 0.07 0.07 0.21 0.19 0.18 0.17 0.16 0.16 0.34 0.22 0.15 0.05 0.05 0.07 0.08 0.78 1.00 
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5.3.3 Factor Analysis 
Factor loadings (cut-off >0.35) from exploratory factor analysis are shown in Table 
5.2. The factor analysis solution which most closely matched WARD’s hierarchical 
cluster analysis was the principal components factor extraction method with 
clustering method rotation. Results supported a seven-factor solution which was, on 
the whole, very similar to the cluster solution outlined above. Three items cross-
loaded onto more than one factor. These were self-injurious behaviour (ASD-like 
factor and Eat/Sleep factor), sleeping difficulties (Eat/Sleep factor and Mood/Anxiety 
factor), and disorientation (ASD-like factor and the Neuropsychological factor).  
 
Table 5.2. Factor analysis results identifying a seven-factor solution (cut-off >0.35) 
 
 PA1 PA2 PA5 PA3 PA4 PA6 PA7 
SCread 0.93 0.00 -0.03 0.01 0.00 -0.07 -0.04 
SCwrite 0.77 -0.07 0.10 0.00 0.10 -0.04 0.01 
SCspel 0.76 -0.04 0.00 0.06 -0.06 0.03 0.07 
SCmath 0.60 0.04 0.10 0.06 -0.22 0.13 0.07 
Banx 0.00 0.71 0.03 0.01 -0.08 -0.03 0.11 
Bdep -0.15 0.71 -0.07 0.12 -0.15 -0.03 0.04 
Bshy -0.01 0.41 -0.05 0.04 -0.06 -0.04 0.16 
Bmood 0.01 0.51 -0.06 -0.03 0.04 0.30 0.05 
Bflex 0.17 0.46 0.12 0.02 0.15 -0.01 -0.03 
Bu.lang 0.10 0.20 0.36 -0.01 0.16 0.04 -0.04 
Beye -0.11 0.12 0.37 0.17 -0.01 0.02 0.20 
Bp.diff -0.12 0.23 0.18 0.14 0.00 0.14 0.27 
Brep 0.11 0.16 0.64 -0.17 0.26 -0.13 0.09 
Blang 0.07 -0.20 0.55 0.02 -0.05 0.04 0.31 
Bs.inj 0.05 0.03 0.38 -0.19 -0.05 0.21 0.39 
Baggr -0.01 0.23 -0.02 -0.01 0.06 0.65 -0.01 
Btemp 0.04 0.02 -0.06 -0.07 0.12 0.74 0.04 
Ba.diff 0.15 0.03 -0.19 0.56 0.27 -0.06 0.13 
NPSmem -0.16 0.13 0.05 0.63 0.07 -0.07 -0.11 
NPSatt 0.00 -0.05 -0.18 0.81 0.15 0.01 0.13 
NPSd.task 0.24 0.08 0.03 0.64 -0.08 0.06 -0.16 
NPSexe 0.03 0.06 0.25 0.68 -0.06 0.02 -0.18 
NPSdisor -0.12 0.03 0.40 0.50 0.03 -0.06 -0.11 
NPSv.spat 0.03 -0.15 0.59 0.33 -0.17 -0.07 0.05 
Bo.act -0.18 -0.11 0.15 0.11 0.73 0.13 -0.17 
Brestl -0.10 -0.02 0.14 0.02 0.62 -0.10 0.18 
Bimpul 0.08 0.04 -0.12 0.22 0.43 0.18 -0.06 
Beat 0.09 0.15 0.13 -0.05 0.05 -0.06 0.44 




5.3.4 Internal Consistency 
Using Chronbach’s alpha to evaluate internal consistency in the cluster analysis 
solutions, 5 clusters scored > 0.7 indicating good to excellent internal consistency 
(see Table 5.3): Scholastic (0.97), Neuropsychological (0.87), ASD-like (0.76), 
Behavioural Dysregulation (0.74), and Overactive/Impulsive (0.70). The remaining 2 
clusters had lower alpha values: Mood/Anxiety (0.69) and Eat/Sleep (0.48). In the 
factor analysis solutions 6 factors showed good to excellent internal consistency (see 
Table 5.4): Scholastic (0.97), Neuropsychological (0.86), ASD-like (0.79), 
Behavioural Dysregulation (0.75), and Overactive/Impulsive (0.70). Only the 
Eat/Sleep factor scored <0.7 with an alpha = 0.54, suggesting poor internal 
consistency. 
 
Table 5.3. Descriptive statistics for the seven natural TAND clusters identified through WARD’s 
method. Cronbach alpha ≥ 0.7 indicates good internal consistency 
 
Cluster No. of Items Alpha 
Scholastic 4 0.97 
Neuropsychological 7 0.87 
Mood/Anxiety 4 0.69 
ASD-Like 5 0.76 
Behavioural Dysregulation 4 0.74 
Hyperactive/Impulsive 3 0.70 
Eat/Sleep 2 0.48 
 
Table 5.4. Descriptive statistics for the seven TAND Factors identified through Exploratory Factor 
Analysis. Cronbach alpha ≥ 0.7 indicates good internal consistency. 
 
Cluster No. of Items Alpha 
Scholastic 4 0.97 
Mood/Anxiety 6 0.74 
ASD-like 7 0.79 
Behavioural Dysregulation 2 0.75 
Neuropsychological 6 0.86 
Overactive/Impulsive 3 0.70 




5.3.5 Comparison of cluster analysis and factor analysis findings 
Factor analysis confirmed a similar profile found in cluster analysis, but with some 
slight variance between clusters and factors (Figure 5.3). Cluster and factor analysis 
showed the ‘Overactive/Impulsive’ and ‘Scholastic’ clusters to be clearly distinct, the 
‘Mood/Anxiety’ and ‘Neuropsychological’ clusters to be fairly distinct, while the other 
three clusters/factors showed more evidence of cross-loading between items in 
different clusters/factors. 
 
Figure 5.3. Relationship between natural TAND Clusters and Factor Analysis. Results show two 
distinct clusters (Scholastic and Overactive/Impulsive), three fairly distinct (Mood/Anxiety, 
Neuropsychological, Eat/Sleep), and significant cross-loading between the other two clusters (ASD-




TSC-Associated Neuropsychiatric Disorders (TAND) have largely gone undiagnosed 
and untreated despite affecting nine out of ten individuals with TSC. This is mainly 
due to lack of awareness, apparent unique TAND profiles, and a lack of knowledge 
and experience in treating TAND. We proposed that the identification of naturally 
occurring TAND clusters may improve assessment and intervention. In a pilot 
feasibility we showed that a data-driven approach may be able to identify natural 































suggestion, findings required larger-scale replication and extension, particularly to 
evaluate the robustness of proposed natural TAND clusters. In this study various 
cluster analysis techniques and exploratory factor analysis was applied in a large and 
diverse international sample (n= 453). In addition, bootstrapping and internal 
consistency analyses were performed.  
 
Results identified seven natural TAND clusters, and bootstrapping showed 5 of the 7 
clusters to be statistically robust. The two apparently less robust clusters were the 
‘Dysregulated Behaviour’ and ‘ASD-like’ clusters. Two of the items clustered with 
Dysregulated Behaviours (self-injury and language delay) showed stronger 
association with the ASD-like cluster using bootstrapping, suggesting that these may 
more appropriately be linked to the ASD-like cluster. 
 
Exploratory factor analysis showed that a 7-factor solution mapped well onto the 
majority of clusters, but with the greatest cross-loading between the ASD-like, 
Dysregulated Behaviour and Mood/Anxiety clusters. The Scholastic, 
Neuropsychological, Overactive/Impulsive, and Eat/Sleep clusters otherwise showed 
good agreement between clusters and factors.  
 
Internal consistency for clusters and factors was good to excellent internal for 5/7 of 
the clusters generated (except for the Mood/Anxiety and Eat/Sleep clusters) and 6/7 
of the factors identified (except for the Eat/Sleep factor). 
 
In slight contrast to the initial pilot feasibility study (Leclezio et al., 2017, under 
review) which suggested 6 natural TAND clusters, this larger-scale study identified 7 
TAND clusters. In this study, the two biological or vegetative items (sleeping/eating) 
grouped together, whereas in the pilot study they were incorporated into the ASD-like 
cluster (difficulties with eating) and the Mood/Anxiety cluster (sleep difficulties). The 
remaining 6 clusters, however, were remarkably similar to the findings from the pilot 
study, reproducing the same clusters, with a few items cross-loading and/or 
represented elsewhere.  
 
5.4.1 Proposed Natural TAND Clusters 
Taking together all results, we propose the following 7 natural TAND clusters for 
future use in clinical practice and research (see Table 5.5). 
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1. Scholastic cluster 
The first of the seven natural TAND clusters identified is a ‘Scholastic’ cluster 
indicating difficulties relating to reading, writing, spelling and mathematics. The items 
in the Scholastic cluster (rendered by both cluster analysis and factor analysis) 
showed perfect bootstrapping, very high factor loadings and alpha scores, indicating 
the close relationship and reliability between items. Findings highlight the need for 
assessment in this cluster if an individual shows signs of difficulty across any one of 
the four items. Academic difficulties are a common concern in TSC (Joinson et al., 
2003; de Vries, 2010a; Kingswood et al., 2017) and not only affects school-aged 
children, but also have long-term consequences in adulthood. 
 
2. Overactive/Impulsive cluster 
Both cluster analysis and factor analysis included overactivity, restlessness, and 
impulsivity in this cluster. Bootstrapping and internal consistency were very good, 
indicative of the reliability of items and how they group together. This cluster appears 
very meaningful given the high rates of ADHD reported in TSC (Prather and de Vries, 
2004; de Vries, 2010a). However, it is of interest that the cluster did not include 
attentional difficulties, which were grouped in the neuropsychological cluster. This 
may suggest ADHD in TSC to be more typically of the ‘predominantly 
hyperactive/impulsive subtype’, or could suggest that there may be differential 
pathways to the attentional and hyperactive/impulsive deficits seen in TSC. 
 
3. Neuropsychological cluster 
This cluster includes memory deficits, disorientation, neuropsychological attention 
deficits as well as attention deficits in daily life, dual task deficits, executive deficits, 
and visuo-spatial deficits. Whilst visuo-spatial deficits was grouped within the ASD 
factor, cluster analysis grouped visuo-spatial deficits with the other 
neuropsychological skills. Bootstrapping supported the clustering with 
neuropsychological skills, but confirmed a frequent co-occurrence with the scholastic 
cluster. Taking all data together, we propose to group visuospatial skills within the 
neuropsychological cluster, a recommendation we believe also makes clinical sense. 
Based on the existing TSC literature, the cluster maps very well onto the high rates of 
a range of neuropsychological attentional, executive, and memory deficits reported 
(Ridler et al., 2007; de Vries, et al., 2009; de Vries, 2010a; Tierney et al., 2011). 
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4. Mood/Anxiety cluster 
Four items are proposed in this cluster – anxiety, depressed mood, mood swings and 
extreme shyness. We observed that factor analysis included inflexibility and sleep-
related problems with the four other items. However, bootstrapping classified these 
two items in the mood/anxiety cluster only 19% - 29% of the time. Given the cluster 
analysis and bootstrapping observed, we propose to group inflexibility with ASD-like 
features, and ‘sleep difficulties’ with the Eat/Sleep cluster. The remaining four items 
(mood swings, anxiety, depressed mood, extreme shyness) are often seen in 
children and adults with TSC (Lewis et al., 2004; de Vries et al., 2007; de Vries, 
2010a; Kingswood et al., 2017).  
 
5. Behavioural Dysregulation cluster 
The behavioural dysregulation cluster includes aggressive outbursts and temper 
tantrums. Cluster analysis included self-injurious behaviour and delayed language 
also in the cluster. However, bootstrapping did not support the robustness of these 
items in the cluster. Instead, both bootstrapping and factor analysis showed stronger 
support for self-injury and delayed/absent language to be part of the ASD-like cluster. 
One of the biggest concerns to families is the high rate of ‘behaviours that challenge’ 
seen in TSC specifically with regards to aggression and temper tantrums, self-injury 
and damage to property (Prather and de Vries, 2004; de Vries et al., 2007; de Vries, 
2010a; Eden et al., 2016; Wilde et al., 2017). It was therefore of interest that a 
specific and distinct cluster of dysregulated behaviours was identified here. 
 
6. ASD-like cluster 
This natural TAND cluster includes 7 items - inflexibility, unusual language, repetitive 
behaviour, poor eye contact, peer difficulty, self-injury, and delayed/absent language. 
As outlined above, initial cluster analysis did not include ‘self-injury’ and ‘delayed 
language’ in the ASD-like cluster, but bootstrapping and factor analysis suggested 
these characteristics to be more likely to co-occur with ASD-like rather than with 
other TAND behaviours. TSC is one of the medical conditions most strongly 
associated with ASD (Bolton et al., 2002). It was therefore of interest to see the 
natural emergence of an ASD-like cluster of behaviours (Bolton et al., 2002; Prather 
and de Vries, 2004; de Vries, 2010a). From a clinical perspective, the strong 
association between self-injury and delayed language maps well onto other studies in 
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TSC (Eden et al, 2014; Wild et al., 2017). Even though we proposed placing self-
injury in the ASD-like cluster there is clear cross-loading also with the ‘Sleep/Eat’ 
cluster reinforcing the finding by Wilde and others that self-injury can be associated 
with a range of manifestations.  
 
7. Eat/Sleep cluster 
This cluster includes eating and sleep difficulties. Sleeping and eating are such 
fundamental biological or vegetative functions that it was not surprising to see them 
cluster together. This cluster was not identified in the pilot study, but this much larger 
sample suggested that these concerns group together reliably. Importantly, both 
sleep and eating difficulties cross-load with other clusters, underlining the fact that 
they often co-occur with other neuropsychiatric difficulties. However, the fact that they 
cluster independently suggests the need to investigate these in their own right, not 
only in the context of other so-called co-morbid conditions. 
 
Table 5.5. Proposed seven natural TAND clusters with items contained in each cluster; and 
Chronbach’s alpha scores per cluster 
 
Cluster No. of Items Items Alpha 









Neuropsychological 7  Memory 
 Disorientation 
 Attention difficulties (behaviour) 




 Executive skills 
0.87 
Mood/Anxiety 4  Mood swings 
 Anxiety 
 Depressed mood 
0.69 
82  
 Extreme shyness  
Behavioural Dysregulation 2  Aggressive outbursts 
 Temper tantrums  
0.75 
ASD-Like 7  Inflexible  
 Unusual language 
 Repetitive behaviour  
 Poor eye contact 
 Peer difficulties 
 Self-injury 
 Delayed language 
0.80 
Eat/Sleep 2  Eat  
 Sleep  
0.48 
 
* Cronbach alpha > = 0.7 indicates internal consistency 
 
5.4.2 Limitations  
Firstly, the TAND Checklist was used here to identify potential natural TAND clusters 
and no other sources of information that may be relevant in cluster analysis or factor 
analysis, such as clinical evaluations or neuropsychological assessments were 
included. We acknowledge that it is therefore theoretically possible that other clusters 
and factors may be identified using different kinds of multi-level data. However, we 
specifically wanted to use the TAND Checklist for this purpose, given that it is a 
simple, yet systematic, and freely available tool that could easily be implemented in 
real life settings around the globe. As reported earlier, pilot validation of the TAND 
Checklist (Leclezio et al., 2015) indicated that the TAND Checklist was a valid tool in 
extrapolating multi-level neuropsychiatric manifestations in TSC. Secondly, we 
acknowledged that all the data were ‘lifetime’ data. We have therefore not been able 
to examine the developmental pattern of natural TAND clusters, which may have a 
more dynamic nature than captured in our work. However, we hope that our findings 
will set the scene to examine longitudinal aspects of natural TAND clusters in future 
large-scale studies. Thirdly, the current TAND Checklist collects data in a 
dichotomous fashion. The study was therefore not able to explore the subtleties of 







This study set out to replicate and expand the potential of identifying natural TAND 
clusters from a large range of apparently independent neuropsychiatric features in 
individuals with TSC. Based on the largest collection of TAND Checklist data to date, 
our analyses generated seven natural TAND clusters that were statistically robust, 
and seemed to have good clinical face validity.  
 
We therefore propose the identification of these clusters to be a useful first step as a 
guide to further assessment and treatment options in clinical practice. Next steps 
could include the development of targeted teaching and training to professionals and 
individuals with TSC around the seven natural TAND clusters, and identification of 
appropriate evidence-based resources and interventions that map onto these 
clusters. At a scientific level, we propose that identification of these naturally-
occurring clusterings of the neuropsychiatric phenotype of TSC may be the first step 
towards a more dimensional, data-driven approach to the study of the aetiology and 
treatments (molecular and otherwise) of individuals with TSC. 
 
5.6 Chapter Summary 
 
Tuberous Sclerosis Complex (TSC) is associated with a wide range of behavioural, 
psychiatric, intellectual, learning, neuropsychological and psychosocial difficulties. 
The lifetime prevalence of these TSC-Associated Neuropsychiatric Disorders (TAND) 
is in the region of 90%. Each individual appears to present with their very own unique 
TAND profile, posing significant challenges for diagnosis, psycho-education, and 
intervention planning. Identifying natural TAND clusters will significantly improve our 
ability to identify and treat TAND. A recent pilot study showed that a combination of 
cluster analysis and factor analysis methods may be able to identify clinically-
meaningful natural TAND clusters. In this study we set out to confirm and expand 
these findings in a larger dataset. TAND Checklist data were collected from 453 
individuals across 6 international sites with a confirmed clinical diagnosis of TSC. 
Using R, the open-source statistical platform, mean squared contingency coefficients 
were calculated to produce a correlation matrix, and various cluster analyses and 
exploratory factory analysis (EFA) were examined. To examine the statistical 
robustness of clusters rendered, bootstrapping was applied. Thereafter Chronbach’s 
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alpha was calculated to measure internal consistency of clusters and factors. 
WARD’s method rendered seven natural TAND clusters with good robustness on 
bootstrapping. Cluster analysis showed significant convergence with an exploratory 
factor analysis solution, and, with the exception of one cluster, the internal 
consistency of the emerging clusters were good to excellent. Taking together all 
findings, seven natural TAND clusters with good clinical face validity are proposed. 
These include a ‘Scholastic’ cluster, an ‘Overactive/Impulsive’ cluster, a 
‘Neuropsychological’ cluster, a ‘Mood/Anxiety’ cluster, a ‘Behavioural Dysregulation’ 
cluster, an, an ‘ASD-like’ cluster, and an ‘Eat/Sleep’ cluster. In this study, we used a 
data-driven computational approach and identified seven natural TAND clusters from 
within highly variable TAND Checklist data. The larger-scale study findings were 
remarkably consistent with pilot findings, supporting the robustness of these naturally 
occurring clusters. We propose that these seven natural TAND clusters could be 
used to develop novel approaches to identification and treatment of TAND. Our 
results suggest that these natural TAND clusters may have differential aetiological 








TSC-Associated Neuropsychiatric Disorders (TAND) comprise some of the 
greatest concerns to families and individuals with TSC, contributing very 
significantly to the burden of disease in TSC. Unfortunately, these concerns 
have gone largely undiagnosed and untreated due to lack of awareness, 
knowledge and resources for TAND. In order to raise awareness of these 
difficulties, the term TAND was coined and a TAND Checklist developed to aid 
clinicians in the systematic review of the range of neuropsychiatric 
manifestations seen. However, another obstacle to the assessment and 
treatment of TAND has been the perceived overwhelming uniqueness of TAND 
profiles observed. To many clinicians around the globe, the vast range and 
different levels of potential difficulties, often co-occurring and changing with 
time, simply left them unable to know where to start and what to do. In this 
thesis, the general aim was to identify natural TAND clusters, with the objective 
of reducing this perceived overwhelming uniqueness of individual TAND 
profiles. The specific aims included an overview of the neuropsychiatric 
phenotype observed in TSC, a reflection on the current challenges faced when 
striving to address TAND in both a clinical setting and from a research 
perspective, a pilot feasibility study to identify appropriate data-reduction 
techniques that may be able to generate natural TAND clusters, and finally a 
larger-scale study to identify natural TAND clusters proposed to be used by 
clinicians in the assessment and treatment of TAND, and by researchers in their 
quest for a better understanding of the aetiology and mechanisms underlying 





6.2 Thesis Overview and Conclusions 
 
In chapter 1, we outlined the thesis and presented a review of the physical 
characteristics and molecular understanding of TSC. In chapter 2, we reviewed 
the neuropsychiatric phenotype observed in TSC with a focus on recent 
advances of relevance to psychiatry, neuropsychiatry and the mental health of 
individuals with TSC. Chapter 3 hypothesised that natural TAND clusters may 
exist and proposed that the reduction of complexity seen in TAND could be 
achieved by searching for such clusters. In chapter 4, the pilot feasibility study 
was presented, which, using a modest sample, identified suitable methods for 
cluster and factor analysis. Using these methods, six potential natural TAND 
clusters were identified. Results therefore suggested that it may indeed be 
possible to use these techniques to generate natural clusters with good clinical 
face validity. In chapter 5, the main data chapter of the thesis, we applied the 
data-reduction techniques identified in the pilot study to a significantly larger 
sample for the identification of natural TAND clusters. Combining cluster 
analysis, bootstrapping, factor analysis and calculation of internal consistency 
across clusters and factors, we proposed seven natural TAND clusters. These 
were a Scholastic cluster, a Neuropsychological cluster, an 
Overactive/Impulsive cluster, a Dysregulated Behaviour cluster, a Mood/Anxiety 
cluster, an ASD-like cluster, and an Eat/Sleep cluster.  
 
6.3 Implication of this research 
 
6.3.1 Educating a wide range of healthcare and other professionals 
One of the obstacles identified in this thesis refers to treatment paralysis i.e. the 
fact that many professionals, including mental health professionals, do not feel 
as though they have enough knowledge/expertise to treat neuropsychiatric 
manifestations observed in TSC, despite being the treating team. With the 
identification of natural TAND clusters, one can now customise and develop 
training materials based on the characteristics of each cluster. The 
development of a TAND curriculum, guided by these seven clusters, may prove 
to be very helpful in educating a range of professionals and clinicians, from 
support workers, healthcare workers, to nurses, therapists and physicians. The 
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hope is that empowering a wide range of healthcare and other professionals, 
should ultimately address the lack of assessment and treatment of TAND 
currently seen in the TSC community. 
  
6.3.2 Educating parents, carers and individuals with TSC 
We propose that the seven natural TAND clusters can also become the basis 
for education of parents, carers and individuals with TSC as a strategy to 
empower them to be able to do early identification of ‘red flags’ and concerns 
about TAND, to know what they can do to manage aspects of TAND, and to 
know how and when to seek additional professional support, assessment or 
treatment.  
 
6.3.3. Linking resources to newly proposed natural TAND clusters 
In support of the educational potential of the natural TAND clusters outlined 
above, the development of a TAND toolkit consisting of tools, tried and tested 
interventions and local resources to guide clinicians and families, will 
complement any educational strategies. We propose that the identified natural 
TAND clusters could play a critical role in the development of such a toolkit. 
These seven clusters may be used to organise resources into groups (clusters) 
that make clinical sense, pre-empt potential other difficulties associated with the 
specific cluster, and ensure a comprehensive inclusion of interventions.    
 
6.3.4 New directions in the aetiology and molecular treatment of TAND 
Traditionally, treatment options for TAND have been the same as standard of 
care for a typical diagnosis of ADHD, for example. However, with the advent of 
molecular targeted treatment options in TSC (specifically mTOR inhibitors), 
there has been great interest in the potential of mTOR inhibitors to modulate or 
treat neuropsychiatric manifestations. In a recent study by Krueger and 
colleagues (2017) the team investigated the effect of mTOR inhibitors on 
various aspects of TAND, including a range of neuropsychological skills, 
academic/scholastic skills and ASD-like characteristics. The results, based on a 
randomised-controlled trial of about 50 participants, did not seem to identify any 
obvious signals of change in relation to mTOR inhibition treatment. In a recent 
presentation, prior to the release of the Krueger et al findings (Leclezio and de 
Vries, 2016b), we suggested that there may be many different reasons why 
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clinical trials of TAND may be difficult. Using data from the TESTALL trial 
(Davies et al., 2011), we showed that factors include the challenge of differing 
baseline scores between participants, challenges in the specific assessment 
tools used, timing of assessment during trial and at completion, duration of 
treatment, and potentially highly variable individual treatment responses 
(Leclezio and de Vries, 2016b). The identification of the seven natural TAND 
clusters in this thesis opens up the possibility that different natural TAND 
clusters may have differential responses to mTOR inhibitor treatments. This, in 
turn, may suggest that different clusters may be subserved by different 
molecular mechanisms. Utilisation of the newly identified natural TAND clusters 
may therefore inform the development of novel trial design and outcome 
measures. Apart from molecular mechanisms, we propose that different natural 
TAND clusters may also have differential structural brain correlates, and 
genotype-phenotype correlations.  
 
 
6.4. Limitations of this study 
 
6.4.1 During these studies, the TAND Checklist was the only tool used to 
identify potential natural TAND clusters. Therefore, there are no additional 
sources of information that may be relevant in cluster analysis. We 
therefore acknowledge that data-reduction approaches using different 
types of data may render different natural TAND clusters. However, pilot 
validation of the TAND Checklist (Leclezio et al., 2015) indicated that the 
TAND Checklist was comprehensive and valid tool in extrapolating 
multilevel neuropsychiatric manifestations observed in TSC. In addition, 
we specifically wanted to explore clustering and data reduction using the 
TAND Checklist, in the hope that this may increase the clinical usefulness 
and global reach of the Checklist.  
6.4.2 The sample used in the study was derived from a number of international 
TSC clinics, which may not have been completely representative of the 
TSC population as a whole. One might expect clinical data to be skewed 
towards the more severe manifestations of TSC. However, the deliberate 
attempt to get a larger-scale diverse sample of individuals with TSC from 
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six clinics around the globe, aimed to increase the representativeness of 
the sample. An ideal next step would be to evaluate these findings in an 
epidemiological TSC sample. 
6.4.3 We only used the lifetime TAND Checklist, and data were therefore cross-
sectional in nature. Given the age-related expression and manifestation of 
physical and neuropsychiatric manifestations in TSC, it would be of great 
interest to examine the emergence and development of TAND in a 
longitudinal cohort. 
 
6.5. Future directions 
 
6.5.1 With the application of factor analysis, it is possible to develop a method to 
generate a profile for each individual with TSC that indicates which 
clusters are involved, and to quantify the extent to which they are affected 
in that cluster. Such information could be clinically very useful to identify 
and recommend interventions and resources that may benefit the 
individual with TSC and their family in a personalised and targeted way. In 
addition, these clusters and scores may also have direct utility as a 
patient-reported outcome measure of TAND in pharmacological and non-
pharmacological clinical trials and in the context of service evaluation. 
6.5.2 The development of a TAND toolkit will be beneficial in directing clinicians 
and families to relevant resources, such as good practice guidelines, 
evidence-based interventions and local resources for support. 
6.5.3 TSC stakeholders very strongly endorse the need for a patient-reported, 
accessible version of the TAND Checklist that could identify TAND 
profiles. Very consistently professional and family stakeholders 
recommend the use of technology, specifically the development of a 
TAND Checklist App as preferred mechanism to achieve this goal. 
Development and validation of a smartphone application (TAND-APP) as 
potential self/patient-reported outcome measure for TAND profiles and the 
burden of TAND, could therefore be a very powerful clinical application of 
the findings from this thesis. 
6.5.4 Using the natural TAND clusters and a quantification of the TAND 
90  
Checklist could be very helpful in the scientific study of TAND, from 
longitudinal descriptive studies of the emergence of TAND, to correlational 
studies such as examination of functional and structural contributions to 
TAND, to experimental studies such as examination of the differential 
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Appendix C: Informed Consent  
 
UNIVERSITY OF CAPE TOWN 
DIVISION OF CHILD AND ADOLESCENT PSYCHIATRY 
 
 
PATIENT INFORMATION SHEET 
 
Principal Investigator:   Professor Petrus de Vries 
Ph.D student and project lead:  Loren Leclezio  
This study is for degree purposes 
 
TSC-Associated Neuropsychiatric Disorders (TAND) cluster investigation, 
TOP-TEN prioritisation, and toolkit development 
 
Background 
A study done in the United Kingdom showed that many people with Tuberous 
Sclerosis Complex (TSC) do not get tested for neuropsychiatric disorders such as 
mood disorders, anxiety, autism spectrum disorders, attention difficulties and 
many more. As a result many children and adults with TSC do not get the 
necessary treatment. In 2012 an international panel of experts in TSC decided to 
develop a checklist to help doctors, nurses and other health care professionals to 
identify these difficulties. Many professionals and families feel overwhelmed by 
the complexity of these disorders and say that they do not know where to start 
and how to access relevant information, tips or ‘next step’ approaches. In this 
project we want to see if there are natural TAND Clusters/Groups – combinations 
of behaviours across different levels - that will simplify further evaluations and 
management. 
 
What will I have to do? 
We would like to invite you to join us for a focus group discussion about TSC. In 
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the focus group there will be 8-15 people. We will discuss various treatment 
options, resources, websites, tips and tools that you have found useful. These 
questions will relate to the following TSC-Associated Neuropsychiatric Disorders 
(TAND):  
1. Behavioural items 
2. Psychiatric items 
3. Intellectual disability 
4. Difficulties at school 
5. Difficulties with specific brain skills  
You will have the opportunity to write down 1-3 helpful resources etc. for each 
question, your responses will be kept anonymous. Thereafter, the group will 
discuss the responses provided to help us identify the top resources, tips and 
tools to be included in a draft TAND toolkit. 
 
How long will all of this take? 
The focus group should not last more than about 2 hours.  
 
What will you do with the information I give you? 
Your feedback will be used to generate a draft TAND toolkit.  
 
What will happen to the results/data? 
We will analyse all the data, and use your feedback in the development of a draft 
TAND Toolkit. We will prepare academic manuscripts and send it to scientific 
journals for publication and will present it at conferences to tell other people about 
what we have done.  
 
Will I get paid for taking part? 
You will not get paid for participating in the focus group, but all your reasonable 
travel expenses to participate will be refunded. We will give you a small amount of 
money as a thank you for helping us. We will also give you refreshments during 
the focus group.  
 
How will this affect me or my child’s treatment?  
Whether you decide to take part or decide not to, it will have no affect on the 
standard of care that you or your child is currently receiving. You may withdraw 
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from the study at any point. 
 
Will the discussions be confidential?  
Participants in the focus group will be reminded to respect confidentiality of others 
and not talk about what they said outside the group. The information given by 
people in the focus group will not be linked to their names in any way. The 
recording for the focus group will be destroyed after it has been transcribed and 
typed up by the research team. 
 
If you have any questions or queries about the research or about helping us in our 
research, please contact Loren Leclezio: (cell) 082 4420351 (email) 
loren.leclezio@uct.ac.za or Professor de Vries,  (telephone) +2721 6854103 
(email) petrus.devries@uct.ac.za 
You can also contact your local TSC physician or organization for more information, 
herewith contact details: 
……………………………………………………………………………………………… 
 
This is phase II(b) of a larger study looking at identifying natural 
clusters/groupings if TSC-Associated Neuropsychiatric Disorders (TAND). In this 
phase we hope to obtain your feedback on resources, references, tips and tools 
that you have found useful and would recommend other families and 
professionals consider. We would also like your recommendations in terms of the 
best format in which to make this information available. This information will be 
used to generate a draft TAND toolkit. 
 
 
Risks & Benefits 
This study involves no more than minimal risk. The information gathered from the 
research team will be available to the treating physicians and clinical team 
working with the TSC patients. Findings from the study will be used in the 
development of a TAND toolkit to assist clinicians and families/individuals with 
TSC in to identify TAND early, to effectively manage clinical, psychological and 




End of Study 
At the end of the study (which involves two phases), two to three manuscripts will 
be prepared for submission to peer-reviewed international journals. The results 
will be submitted for presentation at international conferences relevant to TSC and 
the findings will be shared with participating organisations and individuals in 
appropriate formats. 
 
The study has been explained to me, and my questions have been answered. I 
understand that participation in this study is voluntary, and that I may withdraw 
from the study at any point. I understand that confidentiality cannot be assured 
when participating in a focus group. Outcomes from the focus group will be 
anonymous. I consent to participate in this study. 
 
Do you agree to have the discussions recorded for later analysis? Yes No 
 














I have explained the study to the participant, and in my opinion s/he understands 









Loren Leclezio     Prof Petrus de Vries 
Ph.D student    Sue Struegmann Professor of  
Division of Child and Adolescent Psychiatry Child and Adolescent Psychiatry 
University of Cape Town   University of Cape Town 
Loren.leclezio@uct.ac.za   petrus.devries@uct.ac.za 
(082 4420351)      (021) 6854103 
Participants in this study may contact the UCT Faculty of Health Sciences 
Human Research Ethics Committee (HREC) with any ethical concerns or 
questions about your welfare as a study participant. 
Room E52-24 Old Main Building 
Groote Schuur Hospital 
Observatory 7925 

















Appendix D: Chapter 4 supporting material 
 
Additional File 1: R code for analysis of data 
 
# code Yes = 1, No = 0 
dat.coded <- matrix(0, nrow=nrow(datmat), ncol=ncol(datmat)) 
for (j in 1:ncol(datmat)) 
dat.coded[,j] <- as.numeric(datmat[,j])-1 
# compute mean square contingency coefficient from coded data 
cormat <- cor(dat.coded, use="pairwise.complete.obs") 
# convert correlation to dissimilarity 
D.mat <- 1-cormat 







ave.sil.wd <- rep(NA, 10) 
for (k in 2:10) 
ave.sil.wd[k] <- pam(as.dist(D.mat), k=k)$silinfo$avg.width 
plot (1:10, ave.sil.wd, type="b") 
# optimal number of clusters = max ave sil width 
out <- pam(as.dist(D.mat), k=6)$clustering 
out <- fanny(as.dist(D.mat), k=6)$clustering 
plot(diana(as.dist(D.mat)) 
# chosen cluster solution 
clus.out <- cutree(hclust(d=as.dist(D.mat), method="ward.D2"),k=6) 
elements <- levels(factor(clus.out)) 
G <- matrix(0, nrow = length(clus.out), ncol = length(elements)) 
colnames(G) <- elements 
for (i in 1:length(elements)) G[clus.out == elements[i], i] <- 1 
# Factor analysis 
require(psych) 
# Congruence 
congru <- function(datmat, nfactors=6, fm="minres", rotate="oblimin") 
{ 
fa.solution <- fa(datmat, nfactors=nfactors, fm=fm, rotate=rotate) 
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PHI <- factor.congruence(fa.solution$loadings, G) 
I <- diag(max(nrow(PHI),ncol(PHI))) 
while (nrow(PHI)<nrow(I)) PHI <- rbind(PHI, 0) 
while (ncol(PHI)<ncol(I)) PHI <- cbind(PHI, 0) 
SVD <- svd(PHI) 
Q <- SVD$v %*% t(SVD$u) 
nrow(PHI) - sum(diag(PHI%*%Q)) 
} 
# different FA combinations 
combinations <- expand.grid (nfactors = 4:7, fm = c("minres", 
"wls", "gls", "pa", "minchi"), rotate = c("varimax", 
"quartimax", "bentlerT", "equamax", "varimin", "geominT", 
"bifactor", "promax", "oblimin", "simplimax", "bentlerQ", 
"geominQ", "biquartimin", "cluster")) 
out <- rep(NA,nrow(combinations)) 
for (i in 1:nrow(combinations)) 
out[i] <- congru (dat.coded, nfactors=combinations[i,1], fm = 
levels(combinations[i,2])[combinations[i,2]], rotate = 
levels(combinations[i,3])[combinations[i,3]]) 
# Estimating factor scores 
FA.scores <- function(datmat, nfactors=6, fm="minres", 
rotate="bentlerT", scores="regression", cut=0.4) 
{ 
fa.solution <- fa(datmat, nfactors=nfactors, fm=fm, rotate=rotate, 
scores=scores) 
load.mat <- fa.solution$loadings 
score.mat <- fa.solution$scores 
FA.mat <- factor2cluster(fa.solution$loadings, cut=cut) 
datmat <- na.omit(datmat) 
missing.rows <- attr(datmat,"na.action") 
cor.vec <- rep(NA, nfactors) 
if (ncol(FA.mat)==nfactors) 
for (k in 1:nfactors) 
{ 
F.vars <- datmat[,FA.mat[,k]!=0,drop=F] 
L.weights <- load.mat[FA.mat[,k]!=0,k] 
if (ncol(F.vars)>0) 
{ 
F.obs <- apply(F.vars, 1, sum)/ncol(F.vars) 
F.weighted <- rep(NA,length(F.obs)) 




F.scores <- score.mat[-missing.rows,k] 
F.vars <- F.vars[order(F.scores),] 
F.obs <- F.obs[order(F.scores)] 
F.weighted <- F.weighted[order(F.scores)] 
F.scores <- F.scores[order(F.scores)] 
x.vals <- barplot (F.scores, las=2) 




































Additional File 2: Computation of single congruence index value 
 
Let �!" indicate the Tucker index between factor � and cluster �. If there is � 
factors and � clusters, the matrix of Tucker index values is �:�Å~�. If the 
agreement is perfect, each diagonal value will be 1 and each off diagonal 
value will be 0. The single congruence value is therefore chosen to measure 
how close � is to the indicator matrix. 
Orthogonal Procrustes Analysis (Gower, 1971) is a method to fit one matrix 
onto another through multiplication by an orthogonal matrix, which is 
essentially a high dimensional rotation of � to optimally match � by 
minimising 
���� �� − � = �� (�� − �)(�� − �)′ 
The solution is given by � = ��′ where the singular value decomposition of 
�′� = ���′. 
To optimally fit � to �: �Å~� the two matrices needs to be of commensurable 
size. This is the case when � = �. For � ≠ �, padding is used where if � < 
�, �:�Å~� is replaced by �∗ : �Å~� = �� 
while if � > �, �! is replaced by 
�∗ : �Å~� = �� � . 
The difference between the perfect fit measure of one for each factor/cluster 
pair and the optimally fitted �� is measured by the difference in the trace of 
the two matrices 
max �, � − ��(��) 
This measure focus on the matching diagonal elements, rather than the 
overall fit of the optimisation criterion. Perfect fit will yield a value of zero, and 









# Sugnet Lubbe, Department of Statistics and ActSci, March 2017 
# ---------------------------------------------------------------- 
 
  full.data <- read.csv ("TAND cluster Master dataset Phase 1b.csv") 
 
 
  dat.coded <- matrix(0, nrow=nrow(full.data), ncol=ncol(full.data)-5, 
                 dimnames=list(full.data[,1], 
c(colnames(full.data)[c(3:27,31:43)],"ID"))) 
  temp.dat <- full.data[,c(3:27,31:43)] 
  for (j in 1:ncol(temp.dat)) 
    dat.coded[,j] <- as.numeric(temp.dat[,j])-1 
  dat.coded[,ncol(dat.coded)] <- full.data$IMP.0.10 
 
  head(dat.coded) 
 
  clustering.data <- dat.coded[,c(1:19,26:35)] 
  head(clustering.data) 
 
 
# --- correlation matrix 
 
  cormat <- cor(clustering.data, use="pairwise.complete.obs") 
  dim(cormat) 
  D.mat <- 1-cormat 
  dimnames(D.mat) <- dimnames(cormat) <- 
list(colnames(clustering.data),colnames(clustering.data)) 
 
  plot(hclust(d=as.dist(D.mat), method="ward.D2")) 
  rect.hclust (hclust(d=as.dist(D.mat), method="ward.D2"), k=7) 
  Ward.cluster7 <- cutree(hclust(d=as.dist(D.mat), method="ward.D2"), 
k=7) 














  fa.solution <- fa(datmat, nfactors=nfactors, fm=fm, rotate=rotate) 
  PHI <- factor.congruence(fa.solution$loadings, G) 
  I <- diag(max(nrow(PHI),ncol(PHI))) 
  while (nrow(PHI)<nrow(I)) PHI <- rbind(PHI, 0) 
  while (ncol(PHI)<ncol(I)) PHI <- cbind(PHI, 0) 
 
  SVD <- svd(PHI) 
  Q <- SVD$v %*% t(SVD$u) 




#--- 7 clusters Ward 
clus.out <- Ward.cluster7 
elements <- levels(factor(clus.out)) 
G7 <- matrix(0, nrow = length(clus.out), ncol = length(elements)) 
colnames(G7) <- elements 
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for (i in 1:length(elements)) G7[clus.out == elements[i], i] <- 1 
 
# different FA combinations 
  combinations <- expand.grid (nfactors = 4:7, fm = c("minres", "wls", 
"gls", "pa", "minchi"), rotate = c("varimax", "quartimax", 
"bentlerT", "equamax", "varimin", "geominT", "bifactor", "promax", 
"oblimin", "simplimax", "bentlerQ", "geominQ", "biquartimin", 
"cluster")) 
  combinations <- combinations[-c(264,280),] 
  out <- rep(NA,nrow(combinations)) 
  for (i in 1:nrow(combinations)) 
    {  print(combinations[i,]) 
     out[i] <- congru (clustering.data, nfactors=combinations[i,1], fm = 
levels(combinations[i,2])[combinations[i,2]], rotate = 
levels(combinations[i,3])[combinations[i,3]], G=G7)  
    } 
 
  out<-data.frame(combinations,out)[order(out),] 
  out 
 
  fa(clustering.data, nfactors=7, fm='pa', rotate='cluster') 
 
 
# --- Bootstrap analysis 
 
 
  plot(hclust(d=as.dist(D.mat), method="ward.D2")) 
  rect.hclust (hclust(d=as.dist(D.mat), method="ward.D2"), k=7) 
  Ward.cluster <- cutree(hclust(d=as.dist(D.mat), method="ward.D2"), 
k=7) 
  Ward.cluster 
 
bootrep <- function(datmat, k=6) 
{ 
  cormat <- cor(datmat, use="pairwise.complete.obs") 
  D.mat <- 1-cormat 
  dimnames(D.mat) <- dimnames(cormat) <- 
list(colnames(datmat),colnames(datmat)) 
  cutree(hclust(d=as.dist(D.mat), method="ward.D2"), k=k) 
} 
 
  bootrep(clustering.data[sample(1:nrow(clustering.data),20),]) 
 
  require(cluster) 
  n <- nrow(clustering.data) 
  B <- 1000 
  boot.samples <- matrix(sample (1:n, size=n*B, replace=T), ncol=B) 




# --- Reliability measures for clusters and factors 
 
Chronbach <- function (X) 
{ 
  k <- ncol(X) 
  var.vec <- apply(X, 2, var, na.rm=T) 
  sum.Q <- apply(X, 1, sum, na.rm=T) 
  var.sum <- var(sum.Q) 
  return ((k/(k-1))*((var.sum-sum(var.vec))/var.sum)) 
} 
 
alpha.if.deleted <- function(X) 
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{ 
  out <- rep(NA, ncol(X)) 
  for (i in 1:ncol(X)) 
    out[i] <- Chronbach(X[,-i,drop=F]) 
  if (!is.null(colnames(X))) names(out) <- colnames(X) 
  return(out) 
} 
 
  head(clustering.data) 
 
# --- Clusters 
  for (i in 1:7) 
    { 
       X <- clustering.data[,Ward.cluster7==i] 
       print(paste(names(Ward.cluster7)[Ward.cluster7==i],sep=",")) 
       print (Chronbach(X)) 
       print (alpha.if.deleted(X)) 
       
cat("=============================================================
===\n") 
    } 
 
# --- Factors 
  load.mat <- fa(clustering.data, nfactors=7, fm='pa', 
rotate='cluster')$loadings 
  FA.mat <- apply (load.mat, 2, function (x, cut) as.numeric(x>=cut), 
cut=0.35) 
  for (i in 1:ncol(FA.mat)) 
    { 
       X <- clustering.data[,FA.mat[,i]==1] 
       print(paste(names(Ward.cluster7)[FA.mat[,i]==1],sep=",")) 
       print (Chronbach(X)) 
       print (alpha.if.deleted(X)) 
       
cat("=============================================================
===\n") 
    } 
 
  head (clustering.data) 
  ASDclus <- c(13,9,12,10,11,7,8) 
  ASDclus <- clustering.data[,ASDclus] 
  head (ASDclus) 
 
  Chronbach(ASDclus) 
  alpha.if.deleted(ASDclus) 
 
